4-aminopyridine has been researched along with amifampridine in 350 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 101 (28.86) | 18.7374 |
| 1990's | 120 (34.29) | 18.2507 |
| 2000's | 62 (17.71) | 29.6817 |
| 2010's | 66 (18.86) | 24.3611 |
| 2020's | 1 (0.29) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, DD; Geldenhuys, WJ; Lockman, PR | 1 |
| Dai, SP; Huang, HY; Xie, PG | 1 |
| Forrett-Kaminsky, MC; Jost, WH; Mielke, U; Schimrigk, K | 1 |
| Dai, SP; Huang, HY; Xie, PG; Xu, Y | 1 |
| Aiken, SP; Argentieri, TM; Laxminarayan, S; McArdle, JJ | 1 |
| Braga, MF; Rowan, EG | 1 |
| Allgaier, C; Hertting, G; Huang, HY; Jackisch, R; Lauth, D; Rensing, H | 1 |
| Atchison, WD; Shafer, TJ | 1 |
| Delgado, R; Labarca, P; Latorre, R | 1 |
| Kamijo, T; Kido, H; Miwa, A; Nakamura, F; Sugimoto, T; Tomaru, T; Uchida, Y | 1 |
| Matthews, G; Yan, K | 1 |
| Braga, MF; Harvey, AL; Rowan, EG | 1 |
| Delbono, O; Kotsias, BA | 2 |
| Lavoie, PA; Scheer, HW | 1 |
| Molgó, J; Van der Kloot, W | 1 |
| Aubeneau, M; Blanchard, JC; Boireau, A; Doble, A; Dubédat, P; Laduron, P; Miquet, JM; Olivier, V; Richard, F | 1 |
| Angaut-Petit, D; Comella, JX; Faille, L; Molgó, J; Tabti, N | 1 |
| Mawe, GM | 1 |
| Allgaier, C; Hertting, G; Huang, HY; Jackisch, R | 2 |
| Drachman, D; Strichartz, G | 1 |
| Jost, WH; Mielke, U; Schimrigk, K | 1 |
| Newsom-Davis, J; Palace, J; Wiles, CM | 1 |
| Kim, SY; Lee, SB; Sung, KW | 1 |
| Furuta, T; Miyawaki, N; Shigei, T; Yamauchi, H; Yamazaki, F | 1 |
| Dai, SP; Huang, HY | 1 |
| Chang, CC; Hong, SJ | 1 |
| Stolc, S; Vlcková, E | 1 |
| Hollway, TE; Telford, RJ | 1 |
| Fink, K; Göthert, M; Schlicker, E | 1 |
| Montoya, GA; Quevedo, L | 1 |
| Augustine, GJ | 1 |
| Buyukuysal, RL; Holmes, TC; Wurtman, RJ | 1 |
| Gotzsch, U; Meis, S; Wiegand, H | 1 |
| Chalk, CH; Murray, NM; Newsom-Davis, J; O'Neill, JH; Spiro, SG | 1 |
| Manji, H; McKeran, RO; Schwartz, MS | 1 |
| Borst-Pauwels, GW; Theuvenet, AP; van de Mortel, JB | 1 |
| Bever, CT; Camenga, DL; Johnson, KP; Leslie, J; Panitch, HS | 1 |
| Albowitz, B; Ehrenreich, L; Kuhnt, U | 1 |
| Sahashi, K | 1 |
| Hartung, K | 1 |
| Bauer, V | 1 |
| Kojima, H; Kuno, M; Yawo, H | 1 |
| Mallart, A | 2 |
| Lechat, P; Lemeignan, M; Molgó, J; Peradejordi, F | 1 |
| Angaut-Petit, D; Mallart, A | 1 |
| Dreyer, F; Penner, R | 2 |
| el-Fakahany, EE; Lai, WS | 1 |
| Dreyer, F; Penner, R; Petersen, M; Pierau, FK | 1 |
| Zhang, YP; Zheng, W | 1 |
| Kato, A; Nakamura, F; Sugimoto, T; Sumino, S; Tomaru, T; Uchida, Y | 1 |
| Bournaud, R; Mallart, A | 1 |
| Demarest, JR; Finn, AL | 1 |
| Imai, S; Ogawa, Y | 1 |
| Sugimoto, T; Uchida, Y | 1 |
| Scholfield, CN; Steel, L | 1 |
| Simpson, LL | 2 |
| Anderson, AJ; Harvey, AL; Rowan, EG; Strong, PN | 1 |
| Cook, NS | 1 |
| Harvey, RD; Hume, JR | 1 |
| Boegman, RJ; Metcalf, RH | 1 |
| Daube, JR; Low, PA; McEvoy, KM; Windebank, AJ | 1 |
| Bever, CT; Leslie, J | 1 |
| Dasgupta, BR; Molgó, J; Thesleff, S | 1 |
| Molgó, J; Pécot-Dechavassine, M; Thesleff, S | 1 |
| Molgó, J; Siegel, LS; Tabti, N; Thesleff, S | 1 |
| Harvey, AL; Marshall, DL | 1 |
| Goh, JW; Kelly, ME; Pennefather, PS | 1 |
| Gibson, GE; Manger, T | 1 |
| Altes, U; Baur, AM; Hobbach, HP; Jost, D; Racké, K; Schäfer, J; Wammack, R | 1 |
| Chang, CC; Chiou, LC; Hong, SJ; Shieh, BH; Su, MJ | 1 |
| Kápáti, E; Riesz, M; Szporny, L | 1 |
| Khan, AR; Lemeignan, M; Molgo, J | 1 |
| Gibb, AJ; Marshall, IG | 1 |
| Freeman, GB; Gibson, GE; Mykytyn, V | 1 |
| Cruz, F; Montoya, GA; Pezo, P; Roa, J; Villena, F | 1 |
| Bourret, C; Mallart, A; Tabti, N | 1 |
| Kuromaru, O; Sakai, K | 1 |
| Boegman, RJ; Ludwin, SK; Metcalf, R; Riopelle, RJ | 1 |
| Kauffman, JA; Sellin, LC; Siegel, LS; Way, JF | 1 |
| Lundh, H; Nilsson, O; Rosén, I | 3 |
| Matsumoto, M; Riker, WK; Takashima, K | 1 |
| Lechat, P; Lemeignan, M; Uchiyama, T | 1 |
| Montoya, GA; Roa, J | 1 |
| Chaudhry, I; Duncalf, D; Foldes, FF; Goldiner, PL; Harsing, LG; Lalezari, I; Nagashima, H; Sugimori, T; Vizi, ES | 1 |
| Fang, XM; Shi, YL; Wang, WP; Zhang, YP | 1 |
| Uchida, Y | 1 |
| Sonoki, H; Sugimoto, T; Tomaru, T; Uchida, Y | 1 |
| Haydon, DA; Requena, J; Simon, AJ | 1 |
| Scholfield, CN | 1 |
| Mustafa, SJ; Nakazawa, M | 1 |
| Sapru, H; Sundaram, K | 1 |
| Price, JI; Siegel, LS | 1 |
| Hotta, K; Oba, T | 1 |
| Lemeignan, M; Molgó, J; Thesleff, S | 1 |
| Chang, CC; Chiou, LC; Hong, SJ; Jou, MJ | 1 |
| Nakamura, F; Sonoki, H; Sugimoto, T; Sumino, S; Tomaru, T; Uchida, Y | 1 |
| Johnson-Winegar, AD; Sellin, LC; Siegel, LS | 1 |
| Finger, W; Martin, C | 1 |
| Uchida, Y; Yoshinaka, Y | 1 |
| Greenwood, AG | 1 |
| Gibson, GE; Nicholls, DG; Peterson, C | 2 |
| Gundersen, CB; Miledi, R; Parker, I | 1 |
| Chang, CC; Hong, SJ; Lin, HL; Shieh, BH; Su, MJ | 1 |
| Sellin, LC | 1 |
| Thomsen, RH; Wilson, DF | 1 |
| Dasgupta, BR; Sellin, LC; Thesleff, S | 1 |
| Houston, T; Pleuvry, BJ | 1 |
| Apatoff, B; Riker, WK | 1 |
| Chang, CC; Su, MJ | 1 |
| Gibson, GE; Peterson, C | 3 |
| Thompson, S | 1 |
| Molgó, J; Thesleff, S | 1 |
| Durant, NN; Katz, RL; Lee, C; Nguyen, N | 1 |
| Riker, WK; Sasaki, K | 1 |
| Khan, RA; Lemeignan, M | 1 |
| Kirsch, GE; Narahashi, T | 1 |
| Chiarandini, DJ; Stefani, E | 1 |
| Sánchez, JA; Stefani, E | 1 |
| Matsumoto, M; Riker, WK | 1 |
| Apatoff, BR; Riker, WK; Sasaki, K | 1 |
| Franz, P; Galvan, M; Vogel-Wiens, C | 1 |
| Lamiable, D; Lemeignan, M; Millart, H; Vistelle, R | 1 |
| Fehér, O; Gyuris, T; Szente, M | 1 |
| Davis, HP; Gibson, GE; Idowu, A | 1 |
| Agoston, S; Biessels, P; Den Hertog, A; Pielkenrood, J | 1 |
| Aoki, T; Fukushima, K; Ishikawa, J | 1 |
| Lamiable, D; Lechat, P; Lemeignan, M; Millart, H; Molgo, J | 1 |
| Miledi, R; Parker, I; Zhu, PH | 1 |
| Lamiable, D; Millart, H | 1 |
| Durant, NN; Marshall, IG | 1 |
| Bennett, JL; Blair, KL; Pax, RA | 1 |
| Bittner, GD; Fishman, HM; Krause, TL | 1 |
| Chen, W; Hui, CS | 1 |
| Aydin, S; Buyukuysal, RL; Kiran, BK; Ulus, IH | 1 |
| Dong, Z; Zhu, PH | 1 |
| Knot, HJ; Nelson, MT | 1 |
| Huang, HY; Zhou, CW | 2 |
| Kamali, F; Nicholson, E | 1 |
| Beninger, RJ; Boegman, RJ; Jhamandas, K; Mallet, PE; Wirsching, BA | 1 |
| Asano, M; Shibasaki, K; Takenaka, T; Uchida, W | 1 |
| Hertting, G; Jackisch, R; Lauth, D | 2 |
| Aisen, ML; Blass, J; Blau, A; Edelstein, L; Gibson, G; Hatch, J; Kutt, H; Sevilla, D | 1 |
| Bakker, J; Boerma, CE; Rommes, JH; van Leeuwen, RB | 1 |
| Harper, CM; Russell, JW; Windebank, AJ | 1 |
| Huang, HY; Huang, YZ; Xie, PG | 2 |
| Li, L; Zhang, YP | 1 |
| Whiteman, PJ | 1 |
| Fukata, Y; Izawa, T; Izumi, H; Miwa, A; Ogawa, N; Takeuchi, A | 1 |
| Alfaro, A; Chumillas, MJ; Montalar, J; Morata, C | 1 |
| Pécot-Dechavassine, M; Velasco, ME | 1 |
| Bowman, WC; Braga, MF; Harvey, AL; Rowan, EG | 1 |
| Logue, AR; Maciag, CM; Saydoff, JA; Tam, SW; Tinker, WJ; Zaczek, R | 1 |
| Bertelsmann, FW; de Waal, R; Koetsier, JC; Polman, CH; Uitdehaag, BM; van Diemen, HA; van Loenen, AC | 1 |
| Felts, PA; Smith, KJ | 1 |
| Dong, Z; Xu, ZM; Zhu, PH | 1 |
| Canti, C; Marsal, J; Miralles, F; Peres, J; Solsona, C | 1 |
| Bever, CT | 1 |
| Northover, BJ | 1 |
| Mano, Y; Mayer, RF; Takayanagi, T; Tamura, R | 1 |
| Golard, A; Siegelbaum, SA | 1 |
| Martin, TG; Menegazzi, JJ; Plewa, MC; Seaberg, DC; Wolfson, AB | 1 |
| Barrington, PL; Martin, RL; Ten Eick, RE | 1 |
| Brown, SH; Cooke, JD; Freund, HJ; Hefter, H; Toyka, KV | 1 |
| Johansson, S; Lundh, H; Nilsson, O; Rosén, I | 1 |
| Ebisu, H; Eda, M; Fukaya, C; Gohda, M; Hihara, M; Matzno, S; Nakamura, N; Okada, T; Sakashita, H; Takemoto, T | 1 |
| Chai, S; Kolias, TJ; Webb, RC | 1 |
| Howard, JF; Massey, JM; Sanders, DB | 1 |
| Dolly, JO; McGivern, J; Scholfield, CN | 1 |
| Bergin, PS; Hirsch, NP; Miller, DH; Murray, NM | 1 |
| Casanova, B; Rubio, P; Vílchez, JJ | 1 |
| Gilly, WF; Scheuer, T | 1 |
| Kawai, S; Miwa, AY; Nakamura, F; Okada, R; Sugimoto, T; Tomaru, T; Uchida, Y | 1 |
| Chen, XF; Huang, HY; Tang, T | 1 |
| Beech, DJ; Sadraei, H | 1 |
| Adler, M; Macdonald, DA; Parker, GW; Sellin, LC | 1 |
| Cheng-Wen, Z; Hua-Yu, H; Yu-Liang, S | 1 |
| Guglielmi, JM; Molgó, J | 1 |
| Casanova, B; Monte, E; Vílchez, JJ | 1 |
| Smith, AG; Wald, J | 1 |
| Aisen, ML; Blass, J; Edelstein, L; Sevilla, D | 1 |
| Dolezal, V; Hertting, G; Huang, HY; Schobert, A | 1 |
| Miralles, F; Solsona, C | 2 |
| Moyer, M; Van Lunteren, E | 7 |
| Anderson, PA; Bever, CT; Conway, KL; Dhib-Jalbut, S; Hebel, JR; Johnson, KP; Katz, E; Khan, OA; Leslie, J; Milo, R; Panitch, HS | 1 |
| Hertting, G; Jackisch, R; Ries, V | 1 |
| Fukuda, Y; Higashino, R; Jin, H; Kurimoto, T; Sato, R; Tamaki, H | 1 |
| Anlar, B; Ertan, M; Ozdirim, E; Varli, K | 1 |
| Argov, Z; River, Y; Sadeh, M | 1 |
| Carvajal, A; Dueñas, A; Fernández de la Gándara, F; Maroto, M; Nieto, A; Velasco, A | 1 |
| Farlow, MR; Greig, NH; Lahiri, DK; Nurnberger, JI | 1 |
| Arai, Y; Asano, M; Okazaki, T; Shibasaki, K; Takenaka, T; Uchida, W | 1 |
| Gillespie, JI; Wood, PG | 1 |
| Miller, DH; Murray, NM; Rothwell, JC; Sheean, GL; Thompson, AJ | 1 |
| Dooley, DJ; Pugsley, TA; Whetzel, SZ | 1 |
| Claussen, GC; Kim, DS; Oh, SJ | 1 |
| Sanders, DB | 1 |
| Newsom-Davis, J | 2 |
| Massey, JM; Sanders, DB; Tim, RW | 2 |
| Claussen, GC; Kim, DS; Kwon, KH; Mussell, H; Oh, SJ; Tseng, A | 1 |
| Beech, DJ; Prior, HM; Yates, MS | 2 |
| Maddison, P; Mills, KR; Newsom-Davis, J | 2 |
| Arbusow, V; Schulz, P; Strupp, M; Voltz, RD | 1 |
| Sieb, JP | 1 |
| Garland, CJ; Mistry, DK | 1 |
| de Silva, R; Seneviratne, U | 1 |
| Edwards, LJ; Massey, JM; Sanders, DB; Sanders, LL | 1 |
| Adler, M; Capacio, B; Deshpande, SS | 1 |
| Aksu, F; Baysal, F; Inan, SY | 1 |
| Eguchi, K; Fujimoto, T; Fukuda, T; Motomura, M; Nakamura, T; Nakane, S; Nakao, Y; Satoh, K; Suzu, H | 1 |
| Sabbah, S; Scriba, GK | 2 |
| Beech, DJ; Cheong, A; Dedman, AM | 1 |
| Giuliani, G; Pucci, E; Solari, A; Taus, C; Uitdehaag, B | 2 |
| Kawai, M; Ogawa, M; Oishi, K; Oya, Y; Shigeto, H; Yamamoto, T | 1 |
| Ben Ali, A; Carlet, J; Deletie, E; Dock, M; Garrouste-Orgeas, M; Goldstein, F; Karras, A; Misset, B | 1 |
| Astier, A; Bonneville, A; Gibaud, S | 1 |
| Birthelmer, A; Cassel, JC; Jackisch, R; Jeltsch, H; Schweizer, T | 1 |
| Bourque, CW; Buss, RR; Drapeau, P | 1 |
| Berg, T | 1 |
| Maddison, P; Newsom-Davis, J | 1 |
| Leigh, RJ | 1 |
| Brandt, T; Büttner, U; Jahn, K; Krafczyk, S; Schautzer, F; Schüler, O; Strupp, M | 1 |
| Birthelmer, A; Cassel, JC; Jackisch, R; Lazaris, A; Schweizer, T | 1 |
| Benziane, H; Carde, A; Delacour, H; Edouard, B; Flocard, F; Gentes, P; Ghenname, S; Simon, L | 1 |
| Banwell, BL; Engel, AG; Ohno, K; Sieb, JP | 1 |
| Do, B; Goulay-Dufaÿ, S; Graffard, H; Guyon, F; Le Hoang, MD; Pradeau, D; Raust, JA | 1 |
| Beeson, D; Burke, G; Cossins, J; Maxwell, S; Newsom-Davis, J; Nicolle, M; Palace, J; Robb, S; Vincent, A | 1 |
| Shi, YL; Wang, ZF | 1 |
| Bozzao, L; Conte, A; Frasca, V; Inghilleri, M; Lenzi, D; Mainero, C; Pantano, P; Pozzilli, C | 1 |
| Dubrovska, G; Essin, K; Gollasch, M; Huang, Y; Luft, FC; Tsang, SY; Verlohren, S | 1 |
| Halmagyi, GM; Leigh, RJ | 1 |
| Helmchen, C; Kömpf, D; Rambold, H; Sander, T; Sprenger, A; Straumann, D | 1 |
| Birthelmer, A; Cassel, JC; Förstermann, U; Gödtel-Armbrust, U; Jackisch, R; Knörle, R; Lazaris, A; Schweizer, T | 1 |
| Helmchen, C; Rambold, H; Sander, T; Sprenger, A; Zils, E | 1 |
| Bose, C; Landmesser, LT; Plattner, F; Polo-Parada, L | 1 |
| Bever, CT; Judge, SI | 1 |
| Casanova-Sorní, C; Monte-Boquet, E; Pelufo-Pellicer, A; Poveda-Andrés, JL; Romá-Sánchez, E | 1 |
| Debouverie, M; Pittion, S | 1 |
| Boërio, D; Créange, A; Hogrel, JY; Lefaucheur, JP | 1 |
| Cascorbi, I; Deuschl, G; Hagen, K; Lorenz, D; Ufer, M; Volkmann, J | 1 |
| Cho, S; Meriney, SD | 1 |
| Do, B; Goulay-Dufaÿ, S; Guyon, F; Le Hoang, MD; Pradeau, D; Raust, JA | 1 |
| Helmchen, C; Marti, S; Rambold, H; Sander, T; Sprenger, A; Straumann, D; Weber, K | 1 |
| Moyer, M; Pollarine, J; van Lunteren, E | 2 |
| Layzer, RB; Sha, SJ | 1 |
| Armstrong, ML; Dua, AK; Murrant, CL | 1 |
| Gottschalk, S; Helmchen, C; Rambold, H; Sander, T; Sprenger, A; Trillenberg, P | 1 |
| Carli, L; Johnson, EA; Molgó, J; Montecucco, C; Morbiato, L; Rossetto, O | 1 |
| Kishimoto, R; Matsushima, M; Motomura, M; Nakadate, M; Sasaki, H; Shiraishi, H; Tsuji, S; Yabe, I; Yaguchi, H | 1 |
| Ionno, M; Moyer, M; Pollarine, J; van Lunteren, E | 1 |
| Deminière, C; Krim, E; Lagueny, A; Shipley, E | 1 |
| Searl, TJ; Silinsky, EM | 1 |
| Jahn, K; Kalla, R; Rettinger, N; Spiegel, R; Strupp, M; Wagner, J | 1 |
| Hirayama, Y; Ishigaki, K; Ito, Y; Kodaira, K; Murakami, T; Osawa, M; Shishikura, K; Suzuki, H; Yanagisawa, A | 1 |
| Ishida, T; Ishii, T; Kanazawa, K; Munakata, M; Saito, J; Sato, S; Sekine, S; Sugawara, A; Tachihara, M; Tanino, Y; Uekita, K; Watanabe, K | 1 |
| de Kam, ML; den Hartigh, J; Schoemaker, RC; Titulaer, MJ; Tjaden, UR; van Dijk, JG; van Gerven, JM; van Hasselt, JG; Verschuuren, JJ; Wirtz, PW | 1 |
| Argov, Z | 1 |
| Claussen, GG; Hatanaka, Y; Morgan, MB; Oh, SJ | 1 |
| Castañeda-Hernández, G; González-de la Parra, M; Namur, S | 1 |
| Allain, H; Edan, G; Flet, L; Guillard, O; Javaudin, L; Leray, E; Polard, E | 1 |
| Pollarine, J; van Lunteren, E | 1 |
| Ishikawa, K; Kitamura, K; Mizusawa, H; Sumi, T; Tsukui, K; Tsunemi, T | 1 |
| Capková, K; Garcia, CC; Hognason, K; Jacobson, AR; Janda, KD; McArdle, JJ; Moe, ST; Potian, JG; Thyagarajan, B | 1 |
| Lounsbury, D; Quartel, A; Turbeville, S | 1 |
| Suzuki, S | 1 |
| Kalaichelvan, S; Karpagam, J; Sebastian, S; Sundaraganesan, N | 1 |
| Al-Diwani, A; Bouzat, C; Buckingham, SD; Hernando, G; Jones, AK; Jones, R; Maynard, TP; Rayes, D; Sattelle, DB | 1 |
| Gerven, JM; Titulaer, MJ; Verschuuren, JJ; Wirtz, PW | 1 |
| Beeson, D; Embleton, N; Farrugia, ME; Finlayson, S; Fletcher, N; Hill, M; Hilton-Jones, D; Kullmann, D; Leonard, J; Llewelyn, G; Maddison, P; McDermott, C; Morris, M; Nicholl, DJ; Nixon, J; Palace, J; Richmond, S; Silver, N; Sussman, J; Weir, A; Winer, J | 1 |
| Lennertz, J; Quartel, A | 1 |
| Counsell, CE | 1 |
| Bertorini, TE; Igarashi, M; Li, YD; Rashed, H; Tolley, EA; Zeno, M | 1 |
| Keogh, M; Maddison, P; Sedehizadeh, S | 1 |
| Brain, KR; Green, DM; Jones, AC | 1 |
| Maezawa, Y; Nakamura, F; Uchida, Y | 1 |
| Bardins, S; Brandt, T; Claassen, J; Glasauer, S; Hahn, A; Kalla, R; Rettinger, N; Schneider, E; Spiegel, R; Strupp, M | 1 |
| Dittrich, M; Luo, F; Meriney, SD; Stiles, JR | 1 |
| Bailey, S; Beeson, D; Carr, A; Jayawant, S; Lashley, D; McConville, J; Palace, J; Robb, S | 1 |
| Lang, B; Titulaer, MJ; Verschuuren, JJ | 1 |
| Jensen, HB; Ravnborg, MH; Stenager, E | 1 |
| Akiyoshi, T; Kishi, M; Konishi, T; Kubo, S; Maruyama, N; Miyazaki, T; Mori, S; Shigemoto, K; Yamada, S | 1 |
| Anlar, B; Demirci, M; Guven, A | 1 |
| Beeson, D; Belaya, K; Cossins, J; Finlayson, S; Liu, WW; Maslau, S; Maxwell, S; McGowan, SJ; Palace, J; Pascual Pascual, SI; Slater, CR; Twigg, SR; Walls, TJ | 1 |
| Adler, M; Apland, JP; Borrell, A; Deshpande, SS; Murray, B | 1 |
| Alvarez, P; Chen, X; Giudice, LC; Green, PG; Hendrich, J; Irwin, JC; Levine, JD | 1 |
| Holohan, CA; Horrigan, LA; Lawless, GA; Murtagh, MA; Webster, CM; Williams, CT | 1 |
| Maddison, P | 1 |
| Ghazanfari, N; Morsch, M; Phillips, WD; Reddel, SW; Toyka, KV | 1 |
| Beeson, D; Belaya, K; Burke, G; Cossins, J; Finlayson, S; Holton, JL; Norwood, F; Palace, J; Pascual-Pascual, SI; Walls, TJ | 1 |
| Arredondo, J; Hauser, MA; Lara, M; Maselli, RA; McDonald, K; Ng, F; Ngo, M; Nguyen, J; Pham, JM; Stajich, JM; Wollmann, RL; Yi, Q | 1 |
| Airapetian, N; Ammenouche, N; Dupont, H; Friggeri, A; Lemaire-Hurtel, AS; Levrard, M; Mahjoub, Y; Marciniak, S; Marçon, F; Petitjean, M; Seydi, A; Tinturier, F | 1 |
| Baskaran, P; Thyagarajan, B | 1 |
| Asadi, M; Mohammadi, K; Torabi, S | 1 |
| Burgess, RW; Jordanova, A; Morelli, KH; Seburn, KL | 1 |
| Harris, TL; Hixon, MS; Janda, KD; Lowery, CA | 1 |
| Frasso, M; Lacomis, D; Liang, M; Meriney, SD; Reddel, SW; Tarr, TB; Valdomir, G; Wipf, P | 1 |
| Mori-Yoshimura, M; Murata, M; Nakata, T; Nishikawa, A; Ohno, K; Okamoto, T; Oya, Y | 1 |
| Crone, C; Duno, M; Vissing, J; Witting, N | 1 |
| Hanisch, F; Kornhuber, ME; Schneider, I | 1 |
| Hanson, B; Haroldsen, PE; Musson, DG; O'Neill, CA; Quartel, A | 1 |
| Ishida, N; Kobayashi, E; Komai, K; Kondo, Y; Matsushita, R | 1 |
| Almodovar, JL; Bansagi, B; Hasan, BA; Herrmann, DN; Horvath, R; Littleton, JT; Lochmüller, H; Lofra, RM; Logigian, EL; Sowden, JE; Whittaker, RG; Zuchner, S | 1 |
| Allen, JA; Amato, AA; Arnold, WD; Barohn, R; Benatar, M; Bird, SJ; Bromberg, M; Burns, TM; Chahin, N; Ciafaloni, E; Cohen, JA; Corse, A; Crum, BA; David, WS; Dimberg, E; Donofrio, PD; Dyck, PJ; Engel, AG; Ensrud, ER; Ferrante, M; Freimer, M; Gable, KL; Gibson, S; Gilchrist, JM; Goldstein, JM; Gooch, CL; Goodman, BP; Gorelov, D; Gospe, SM; Goyal, NA; Guidon, AC; Guptill, JT; Gutmann, L; Gwathmey, K; Harati, Y; Harper, CM; Hehir, MK; Hobson-Webb, LD; Howard, JF; Jackson, CE; Johnson, N; Jones, SM; Juel, VC; Kaminski, HJ; Karam, C; Kennelly, KD; Khella, S; Khoury, J; Kincaid, JC; Kissel, JT; Kolb, N; Lacomis, D; Ladha, S; Larriviere, D; Lewis, RA; Li, Y; Litchy, WJ; Logigian, E; Lou, JS; MacGowen, DJ; Maselli, R; Massey, JM; Mathews, KD; Mauermann, ML; Meriggioli, MN; Miller, RG; Moon, JS; Mozaffar, T; Nations, SP; Nowak, RJ; Ostrow, LW; Pascuzzi, RM; Peltier, A; Richman, DP; Ross, MA; Rubin, DI; Russell, JA; Ruzhansky, K; Sachs, GM; Salajegheh, MK; Saperstein, DS; Scelsa, S; Selcen, D; Shaibani, A; Shieh, PB; Silvestri, NJ; Singleton, JR; Smith, BE; Smith, GA; So, YT; Solorzano, G; Sorenson, EJ; Sousa, EA; Srinivasen, J; Tavee, J; Tawil, R; Thaisetthawatkul, P; Thornton, C; Trivedi, J; Vernino, S; Wang, AK; Webb, TA; Weiss, MD; Windebank, AJ; Wolfe, GI | 1 |
| Abicht, A; Bestué, M; Camacho, A; Colomer, J; Dusl, M; Evangelista, T; García-Hoyos, M; García-Ribes, A; Jiménez, E; Lochmüller, H; Nascimento, A; Natera-de Benito, D; Ortez, C; Töpf, A; Trujillo-Tiebas, MJ; Vilchez, JJ | 1 |
| Alsharabati, M; Blanco, JM; Brannagan, T; Dimachkie, M; Komoly, S; Kostera-Pruszczyk, A; Lavrnić, D; Meisel, A; Oh, SJ; Schoser, B; Shcherbakova, N; Shieh, PB; Sivakumar, K; So, Y; Vial, C | 1 |
| Alboini, PE; Damato, V; Evoli, A; Iorio, R | 1 |
| Corbitt, TS; Diego-Taboada, A; Harris, TL; Janda, KD; Mackenzie, G; Wenthur, CJ | 1 |
| Alcaide, M; Fekete, L; Gurevich, L; Papaioannou, S; Pennisi, CP; Taylor, A; Zachar, V | 1 |
| Gill, SK; Lee Lo, V; Lee, DC; Maselli, RA; Mazurek, ME; Ng, F; Schrumpf, LA | 1 |
| Mazell, SN; Shah, DA; Verma, S | 1 |
| Chan, KY; Chan, ML; Chang, RS; Lai, T; Lau, VW | 1 |
| Green, DB; Grimsley, CA; Sivaramakrishnan, S | 1 |
| McEnany, PJ | 1 |
| Aleš, K; Cohen-Wolkowiez, M; Gonzalez, D; Guptill, JT; Jacobus, D; Jacobus, L; Peloquin, C; Thakkar, N | 1 |
| Datt, J; Haroldsen, PE; Ingenito, G; Musson, DG; Sisic, Z | 1 |
| Bramanti, A; Bramanti, P; Brizzi, T; Cacciola, A; De Cola, MC; Lupica, A; Milardi, D; Portaro, S; Rodolico, C; Sinicropi, S; Toscano, A | 1 |
| de Jong, MGH; de Wilde, S; Guchelaar, HJ; Lipka, AF; Schimmel, KJM | 1 |
| Bradford, AB; Machamer, JB; McNutt, PM; Russo, TM | 1 |
| Kano, T; Matsushima, M; Naganuma, R; Sasaki, H; Takahashi, I; Yabe, I | 1 |
| Kim, SM; Lee, MK; Sunwoo, IN | 1 |
| Oh, SJ | 1 |
| Dodridge, CS; Evans, JR; Garcia-Finana, M; Hanna, K; Howard, C; Jarvis, KA; Maan, T; MacDiarmid, SL; Noonan, CP; North, L; Rodgers, H; Rowe, FJ | 1 |
| Hong, D; Hong, T; Huang, J; Li, M; Meng, W; Ouyang, T; Zhang, N | 1 |
25 review(s) available for 4-aminopyridine and amifampridine
| Article | Year |
|---|---|
[Presynaptic effects of aminopyridines on the neuromuscular junction of vertebrates].
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Aminoquinolines; Animals; Anura; In Vitro Techniques; Ion Channels; Membrane Potentials; Motor Endplate; Neuromuscular Junction; Potassium; Pyridines; Synaptic Transmission; Vertebrates | 1985 |
[Research progress on a new potassium channel-blocking agent--4-aminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Humans; Ion Channels; Myasthenia Gravis; Potassium | 1986 |
The action of batulinum toxin at the neuromuscular junction.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Botulinum Toxins; Botulism; Calcium; Clostridium botulinum; Humans; Neuromuscular Junction; Neurotransmitter Agents; Synaptic Transmission | 1981 |
The current status of studies of aminopyridines in patients with multiple sclerosis.
Topics: 4-Aminopyridine; Amifampridine; Clinical Trials as Topic; Double-Blind Method; Humans; Multiple Sclerosis; Placebos; Prospective Studies | 1994 |
3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Orphan Drug Production; Potassium Channels | 1996 |
Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Acute Disease; Amifampridine; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Middle Aged; Respiratory Insufficiency | 1996 |
[Diagnosis and therapy of congenital myasthenia syndrome].
Topics: 4-Aminopyridine; Adult; Amifampridine; Central Nervous System Stimulants; Child; Cholinesterase Inhibitors; Edrophonium; Enzyme Inhibitors; Ephedrine; Humans; Infant; Infant, Newborn; Male; Myasthenia Gravis; Potassium Channels; Pyridostigmine Bromide; Quinidine; Syndrome; Thymectomy | 1999 |
Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Anti-Inflammatory Agents; Autoantibodies; Calcium Channels; Carcinoma, Small Cell; Genetic Predisposition to Disease; HLA-B8 Antigen; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Plasma Exchange; Potassium Channels; Prednisolone | 1999 |
Aminopyridines for symptomatic treatment in multiple sclerosis.
Topics: 4-Aminopyridine; Amifampridine; Cross-Over Studies; Humans; Multiple Sclerosis; Potassium Channel Blockers; Randomized Controlled Trials as Topic | 2001 |
Aminopyridines for symptomatic treatment in multiple sclerosis.
Topics: 4-Aminopyridine; Amifampridine; Cross-Over Studies; Humans; Multiple Sclerosis; Potassium Channel Blockers; Randomized Controlled Trials as Topic | 2002 |
Treatment for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Potassium Channel Blockers; Randomized Controlled Trials as Topic | 2003 |
Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous System; Calcium Channels, P-Type; Calcium Channels, Q-Type; Carcinoma, Small Cell; Cholinesterase Inhibitors; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Neoplasm Proteins; Plasmapheresis; Potassium Channel Blockers; Pyridostigmine Bromide | 2004 |
Cure of experimental botulism and antibotulismic effect of toosendanin.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins; Botulism; Drugs, Chinese Herbal; Melia; Neurotransmitter Agents; Plants, Medicinal; Potassium Channel Blockers | 2004 |
Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
Topics: 4-Aminopyridine; Amifampridine; Animals; Humans; Multiple Sclerosis; Neurons; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2006 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central Nervous System; Chronic Disease; Fatigue; Humans; Mental Fatigue; Modafinil; Multiple Sclerosis; Pemoline; Peripheral Nervous System; Physical Exertion; Severity of Illness Index; Surveys and Questionnaires | 2006 |
[Pharmacotherapy of central oculomotor disorders].
Topics: 4-Aminopyridine; Amifampridine; Amines; Baclofen; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Gabapentin; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Memantine; Nystagmus, Pathologic; Vestibular Nuclei | 2008 |
Management of myasthenic conditions: nonimmune issues.
Topics: 4-Aminopyridine; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Humans; Myasthenia Gravis; Myasthenic Syndromes, Congenital; Oligodeoxyribonucleotides, Antisense; Potassium Channel Blockers; Pyridostigmine Bromide; Respiratory Insufficiency | 2009 |
Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Antineoplastic Agents; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Potassium Channel Blockers; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
[Lambert-Eaton myasthenic syndrome (LEMS)].
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Calcium Channels, P-Type; Calcium Channels, Q-Type; HLA Antigens; Humans; Immunotherapy; Lambert-Eaton Myasthenic Syndrome; Paraneoplastic Syndromes, Nervous System; Plasma Exchange; SOXB1 Transcription Factors; Synaptotagmins | 2010 |
3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Calcium Channels; Cholinergic Agents; Clinical Protocols; Epilepsy; Humans; Lambert-Eaton Myasthenic Syndrome; Muscles; Paresthesia; Presynaptic Terminals; Randomized Controlled Trials as Topic | 2010 |
Treatment for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Cholinesterase Inhibitors; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Muscle Strength; Potassium Channel Blockers; Pyridostigmine Bromide; Randomized Controlled Trials as Topic | 2011 |
Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Calcium Channels; Carcinoma, Small Cell; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms | 2011 |
Treatment in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Agents; Guanidine; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Placebos; Potassium Channel Blockers; Pyridostigmine Bromide; Randomized Controlled Trials as Topic | 2012 |
Interventions for eye movement disorders due to acquired brain injury.
Topics: 4-Aminopyridine; Abducens Nerve Diseases; Amifampridine; Amines; Baclofen; Botulinum Toxins; Brain Injuries; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neuromuscular Agents; Nystagmus, Pathologic; Ocular Motility Disorders; Randomized Controlled Trials as Topic; Vision, Binocular; Watchful Waiting | 2018 |
3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Topics: 4-Aminopyridine; Adult; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Randomized Controlled Trials as Topic | 2021 |
26 trial(s) available for 4-aminopyridine and amifampridine
| Article | Year |
|---|---|
3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Electromyography; Female; Humans; Male; Middle Aged; Muscles; Neuromuscular Diseases; Prospective Studies; Time Factors | 1991 |
3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscles; Prospective Studies | 1989 |
Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Aged, 80 and over; Amifampridine; Charcot-Marie-Tooth Disease; Chronic Disease; Cross-Over Studies; Demyelinating Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Electrophysiology; Female; Humans; Male; Middle Aged; Potassium Channels; Prospective Studies; Psychomotor Performance | 1995 |
4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Placebos | 1994 |
3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Topics: 4-Aminopyridine; Amifampridine; Double-Blind Method; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis | 1993 |
A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit.
Topics: 4-Aminopyridine; Administration, Oral; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscle Weakness; Neural Conduction; Potassium Channel Blockers; Psychomotor Performance | 1996 |
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Aged; Amifampridine; Double-Blind Method; Female; Humans; Leg; Male; Middle Aged; Multiple Sclerosis | 1996 |
3,4-diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Electromyography; Female; Humans; Male; Myasthenia Gravis; Neurologic Examination | 1996 |
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Adult; Amifampridine; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscles; Myasthenia Gravis; Prospective Studies | 2000 |
Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Topics: 4-Aminopyridine; Action Potentials; Aged; Aged, 80 and over; Amifampridine; Cerebellum; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Models, Neurological; Nystagmus, Pathologic; Potassium Channel Blockers; Potassium Channels; Prospective Studies; Purkinje Cells; Treatment Outcome; Vestibular Nuclei | 2003 |
Distinct phenotypes of congenital acetylcholine receptor deficiency.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Cell Line; Child; Child, Preschool; Cholinesterase Inhibitors; DNA Mutational Analysis; Drug Therapy, Combination; Electric Stimulation; Electromyography; Electrophysiology; Embryo, Mammalian; Ephedrine; Evoked Potentials, Motor; Female; Fluorescent Antibody Technique; Humans; Kidney; Male; Middle Aged; Muscle Proteins; Muscles; Mutation; Myasthenic Syndromes, Congenital; Phenotype; Potassium Channel Blockers; Protein Subunits; Pyridostigmine Bromide; Receptors, Cholinergic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Severity of Illness Index; Sympathomimetics; Transfection | 2004 |
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Amifampridine; Axons; Cross-Over Studies; Double-Blind Method; Electromyography; Evoked Potentials, Motor; Fatigue; Female; Humans; Magnetic Resonance Imaging; Magnetics; Middle Aged; Motor Activity; Motor Cortex; Multiple Sclerosis, Relapsing-Remitting; Potassium Channel Blockers; Reaction Time; Severity of Illness Index; Synaptic Transmission; Treatment Outcome | 2004 |
No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
Topics: 4-Aminopyridine; Adult; Amifampridine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Essential Tremor; Female; Humans; Male; Placebo Effect; Potassium Channel Blockers; Severity of Illness Index; Treatment Failure | 2006 |
Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Cerebellar Ataxia; Electrooculography; Eye Movements; Female; Gravitation; Humans; Male; Middle Aged; Nystagmus, Physiologic; Potassium Channel Blockers; Prospective Studies | 2006 |
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Humans; Lambert-Eaton Myasthenic Syndrome; Middle Aged; Muscle Strength; Pyridostigmine Bromide; Treatment Outcome | 2009 |
3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cross-Over Studies; Double-Blind Method; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Placebos; Prospective Studies | 2009 |
Quantification of 4-aminopyridine in plasma by capillary electrophoresis with electrokinetic injection.
Topics: 4-Aminopyridine; Administration, Oral; Adolescent; Adult; Amifampridine; Electricity; Electrophoresis, Capillary; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Reference Standards; Reproducibility of Results; Spinal Cord Injuries | 2010 |
3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Child; Cohort Studies; Dyskinesias; Fatigue; Female; France; Humans; Male; Middle Aged; Multiple Sclerosis; Potassium Channel Blockers; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2010 |
Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Cross-Over Studies; Double-Blind Method; Electrophysiology; Fatigue; Female; Humans; Male; Middle Aged; Motor Neuron Disease; Muscle Weakness; Potassium Channel Blockers | 2011 |
Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
Topics: 4-Aminopyridine; Aged; Amifampridine; Capsules; Cross-Over Studies; Double-Blind Method; Eye Movements; Female; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Nystagmus, Pathologic; Potassium Channel Blockers; Prospective Studies; Video Recording | 2011 |
3,4-Diaminopyridine may improve neuromuscular block during botulism.
Topics: 4-Aminopyridine; Action Potentials; Adult; Amifampridine; Botulism; Female; Humans; Neuromuscular Blockade; Pilot Projects; Young Adult | 2013 |
Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Amifampridine; Area Under Curve; Biological Availability; Cross-Over Studies; Eating; Fasting; Female; Food-Drug Interactions; Half-Life; Healthy Volunteers; Humans; Male; Middle Aged; Phosphates; Therapeutic Equivalency; Young Adult | 2015 |
Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Amifampridine; Area Under Curve; Asian People; Cross-Over Studies; Electrocardiography; Fasting; Half-Life; Healthy Volunteers; Heart Rate; Humans; Japan; Metabolic Clearance Rate; Models, Biological; Neural Conduction; Neuromuscular Agents; Nonlinear Dynamics; Postprandial Period; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2015 |
Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Calcium Channels; Double-Blind Method; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Phosphates; Potassium Channel Blockers; Treatment Outcome; Young Adult | 2016 |
Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Arylamine N-Acetyltransferase; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Lower Extremity; Male; Middle Aged; Models, Biological; Muscle Weakness; Polymorphism, Single Nucleotide; Potassium Channel Blockers; Treatment Outcome; Young Adult | 2017 |
Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function.
Topics: 4-Aminopyridine; Acetylation; Adult; Aged; Amifampridine; Female; Humans; Kidney; Male; Middle Aged; Potassium Channel Blockers; Renal Insufficiency | 2017 |
299 other study(ies) available for 4-aminopyridine and amifampridine
| Article | Year |
|---|---|
3-D-QSAR and docking studies on the neuronal choline transporter.
Topics: Binding Sites; Blood-Brain Barrier; Computer Simulation; Membrane Transport Proteins; Models, Molecular; Neurons; Quantitative Structure-Activity Relationship; Quaternary Ammonium Compounds | 2010 |
[Modulation of 3,4-diaminopyridine-evoked norepinephrine release from rat hippocampal slices by activation of alpha 2-adrenoceptor].
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channel Blockers; Clonidine; Hippocampus; In Vitro Techniques; Male; Norepinephrine; omega-Conotoxin GVIA; Peptides, Cyclic; Potassium Channels; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Ruthenium Red; Yohimbine | 1992 |
[Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Electromyography; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Paresthesia | 1992 |
[3,4-Diaminopyridine-evoked norepinephrine release from hippocampal in the absence of extracellular calcium].
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Calcium Channels; Extracellular Space; Hippocampus; Male; Norepinephrine; Phorbol 12,13-Dibutyrate; Polymyxin B; Rats; Rats, Inbred Strains | 1992 |
Characteristics of synaptic transmission in reinnervating rat skeletal muscle.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Cholinesterase Reactivators; Diacetyl; Electrophysiology; Hemicholinium 3; In Vitro Techniques; Motor Endplate; Muscles; Neostigmine; Nerve Endings; Nerve Regeneration; Potassium Channels; Rats; Rats, Inbred Strains; Synapses; Synaptic Transmission; Temperature | 1992 |
Reversal by cysteine of the cadmium-induced block of skeletal neuromuscular transmission in vitro.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Animals; Cadmium; Calcimycin; Calcium; Cysteine; Diaphragm; Female; In Vitro Techniques; Male; Membrane Potentials; Mice; Mice, Inbred BALB C; Motor Endplate; Neuromuscular Junction; Potassium; Synaptic Transmission | 1992 |
Alpha 2-adrenoceptor mediated inhibition of exocytotic noradrenaline release in the absence of extracellular Ca2+.
Topics: 4-Aminopyridine; Amifampridine; Animals; Axons; Calcium; Calcium Channel Blockers; Clonidine; Exocytosis; Extracellular Space; Hippocampus; In Vitro Techniques; Ligands; Nerve Endings; Norepinephrine; omega-Conotoxins; Peptides, Cyclic; Rabbits; Rats; Receptors, Adrenergic, alpha; Signal Transduction | 1992 |
Effects of methylmercury on perineurial Na+ and Ca(2+)-dependent potentials at neuromuscular junctions of the mouse.
Topics: 4-Aminopyridine; Amifampridine; Animals; Barium; Calcium Channels; In Vitro Techniques; Male; Membrane Potentials; Methylmercury Compounds; Mice; Motor Endplate; Motor Neurons; Neuromuscular Junction; Sodium Channels; Synaptic Transmission; Tetraethylammonium Compounds | 1992 |
K(+)-channel blockers restore synaptic plasticity in the neuromuscular junction of dunce, a Drosophila learning and memory mutant.
Topics: 4-Aminopyridine; 8-Bromo Cyclic Adenosine Monophosphate; Amifampridine; Animals; Drosophila; Larva; Learning; Memory; Motor Endplate; Mutation; Neuronal Plasticity; Potassium Channels; Synapses; Synaptic Transmission; Tetraethylammonium; Tetraethylammonium Compounds; Time Factors | 1992 |
[The vasospasmolytic effects of nicorandil, cromakalim and pinacidil on 3,4-diaminopyridine-induced phasic contractions in canine coronary arteries as an experimental vasospasm model].
Topics: 4-Aminopyridine; Amifampridine; Animals; Benzopyrans; Coronary Vasospasm; Cromakalim; Disease Models, Animal; Dogs; Female; Glyburide; Guanidines; In Vitro Techniques; Ion Channel Gating; Male; Methylene Blue; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents | 1992 |
Blockers of potassium channels reduce the outward dark current in rod photoreceptor inner segments.
Topics: 4-Aminopyridine; Amifampridine; Animals; Bufo marinus; Hydrogen-Ion Concentration; Kinetics; Light; Membrane Potentials; Photoreceptor Cells; Potassium Channels; Signal Transduction; Tetraethylammonium Compounds | 1992 |
Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro.
Topics: 4-Aminopyridine; Acetylcholine; Acetylcholinesterase; Action Potentials; Amifampridine; Aminoacridines; Animals; Calcium; Chick Embryo; Cholinesterase Inhibitors; Electrophysiology; In Vitro Techniques; Magnesium; Male; Mice; Mice, Inbred BALB C; Motor Endplate; Neuromuscular Junction; Respiratory Muscles; Synaptic Transmission; Tacrine | 1991 |
Calcium action potentials in innervated and denervated rat muscle fibres.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Apamin; Cadmium; Calcium; Calcium Channels; Electric Conductivity; Muscle Denervation; Muscles; Nifedipine; Rats; Rats, Inbred Strains; Tetraethylammonium; Tetraethylammonium Compounds | 1991 |
Mechanism of aminopyridine-induced release of [3H]dopamine from rat brain synaptosomes.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Brain; Cadmium; Calcium; Calcium Channel Blockers; Calcium Radioisotopes; Cobalt; Dopamine; In Vitro Techniques; Male; Neurotransmitter Agents; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Synaptosomes | 1991 |
Quantal release and facilitation at frog neuromuscular junctions at about 0 degrees C.
Topics: 4-Aminopyridine; Amifampridine; Animals; Cold Temperature; Electric Stimulation; Kinetics; Motor Endplate; Neuromuscular Junction; Neurotransmitter Agents; Ranidae; Synaptic Transmission; Virulence Factors, Bordetella | 1991 |
Differential effects of potassium channel blockers on dopamine release from rat striatal slices.
Topics: 4-Aminopyridine; Amifampridine; Animals; Cations; Corpus Striatum; Dopamine; Male; Potassium Channels; Rats; Rats, Inbred Strains; Sodium Channels; Tetraethylammonium; Tetraethylammonium Compounds | 1991 |
Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Botulinum Toxins; Calcium Channels; Electrophysiology; Female; Ion Channels; Mice; Nerve Endings; Nerve Regeneration; Neuromuscular Junction; Potassium Channels; Receptors, Cholinergic; Tetraethylammonium; Tetraethylammonium Compounds | 1990 |
Intracellular recording from neurones of the guinea-pig gall-bladder.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Apamin; Bethanechol; Bethanechol Compounds; Calcium; Curare; Gallbladder; Guinea Pigs; In Vitro Techniques; Membrane Potentials; Neurons; Serotonin; Substance P; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1990 |
3,4-Diaminopyridine-evoked noradrenaline release in rat hippocampus: role of Na+ entry on Ca2+ pools and of protein kinase C.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Calcium; Cytosol; Hippocampus; In Vitro Techniques; Male; Neurotransmitter Agents; Norepinephrine; Phorbol 12,13-Dibutyrate; Polymyxin B; Protein Kinase C; Rats; Rats, Inbred Strains; Ruthenium Red; Sodium; Tetrodotoxin | 1991 |
Potassium channel blockers potentiate impulse inhibition by local anesthetics.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Bupivacaine; Isotonic Solutions; Lidocaine; Membrane Potentials; Potassium Channels; Rana catesbeiana; Ringer's Solution; Sciatic Nerve; Solutions; Tetraethylammonium; Tetraethylammonium Compounds | 1991 |
Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison.
Topics: 4-Aminopyridine; Amifampridine; Combined Modality Therapy; Electromyography; Follow-Up Studies; Guanidine; Guanidines; Humans; Lambert-Eaton Myasthenic Syndrome; Long-Term Care; Male; Neurologic Examination; Plasmapheresis; Prednisone | 1991 |
Cardiovascular regulation by cholinergic mechanisms in rostral ventrolateral medulla of spontaneously hypertensive rats.
Topics: 4-Aminopyridine; Amifampridine; Animals; Atropine; Brain; Hemodynamics; Male; Parasympathomimetics; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 1991 |
Anti-ischaemic and vasospasmolytic effects of a novel Ca2+ channel blocker, SD-3211, in vitro.
Topics: 4-Aminopyridine; Amifampridine; Animals; Arteries; Calcium Channel Blockers; Coronary Disease; Coronary Vasospasm; Coronary Vessels; Dogs; In Vitro Techniques; Myocardial Reperfusion; Potassium Channels; Rabbits; Thiazoles; Vasoconstriction | 1991 |
[3,4-Diaminopyridine and 4-aminopyridine evoked neurotransmitter release].
Topics: 4-Aminopyridine; Amifampridine; Animals; Female; Hippocampus; Male; Norepinephrine; Phorbol 12,13-Dibutyrate; Polymyxin B; Rabbits | 1991 |
Facilitation by 3,4-diaminopyridine of regenerative acetylcholine release from mouse motor nerve.
Topics: 4-Aminopyridine; Acetylcholine; Acetylcholinesterase; Action Potentials; Amifampridine; Animals; Calcium Channel Blockers; Calcium Channels; Female; In Vitro Techniques; Male; Mice; Mice, Inbred ICR; Motor Endplate; Motor Neurons; Neostigmine; Nerve Regeneration; Neuromuscular Junction; Parasympatholytics; Phrenic Nerve; Receptors, Cholinergic; Tetraethylammonium; Tetraethylammonium Compounds | 1990 |
3,4-Diaminopyridine induced stimulus-bound repetitive firing in frog sympathetic ganglion: no changes in postsynaptic membrane excitability.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Ganglia, Sympathetic; Potassium Channels; Rana esculenta; Rana temporaria; Synaptic Membranes; Synaptic Transmission | 1990 |
The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Anesthesia, General; Glycopyrrolate; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Neostigmine; Potassium Channels; Vecuronium Bromide | 1990 |
Veratridine and other depolarizing agents counteract the inhibitory effect of Mg2+ ions on N-methyl-D-aspartate (NMDA)-induced noradrenaline release in vitro.
Topics: 2-Amino-5-phosphonovalerate; 4-Aminopyridine; Amifampridine; Animals; Aspartic Acid; Dibenzocycloheptenes; Dizocilpine Maleate; Electric Stimulation; Hydrogen; In Vitro Techniques; Magnesium; Male; N-Methylaspartate; Neuromuscular Depolarizing Agents; Norepinephrine; Potassium; Rats; Rats, Inbred Strains; Veratridine; Veratrine | 1990 |
The effects of pentachlorophenol (PCP) at the toad neuromuscular junction.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Anura; Axons; Calcium; Dose-Response Relationship, Drug; Formamides; Membrane Potentials; Neuromuscular Junction; Pentachlorophenol; Sciatic Nerve; Synaptic Transmission | 1990 |
Regulation of transmitter release at the squid giant synapse by presynaptic delayed rectifier potassium current.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Cell Membrane Permeability; Decapodiformes; Ganglia, Sympathetic; In Vitro Techniques; Kinetics; Manganese; Neurotransmitter Agents; Potassium; Potassium Channels; Synapses; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1990 |
Interactions of 3,4-diaminopyridine and choline in stimulating acetylcholine release and protecting membrane phospholipids.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Animals; Choline; Corpus Striatum; Drug Interactions; In Vitro Techniques; Male; Membrane Lipids; Phospholipids; Rats; Rats, Inbred Strains | 1991 |
Inhibition by tetrandrine of calcium currents at mouse motor nerve endings.
Topics: 4-Aminopyridine; Alkaloids; Amifampridine; Animals; Benzylisoquinolines; Calcium Channel Blockers; Calcium Channels; Electric Stimulation; In Vitro Techniques; Mice; Motor Neurons; Neuromuscular Junction; Potassium Channels; Synaptic Transmission; Tetraethylammonium; Tetraethylammonium Compounds | 1990 |
Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Muscles; Recurrence; Survival Analysis | 1990 |
Lambert Eaton syndrome: autonomic neuropathy and inappropriate antidiuretic hormone secretion in a patient with small cell carcinoma of the lung.
Topics: 4-Aminopyridine; Aged; Amifampridine; Carcinoma, Small Cell; Humans; Inappropriate ADH Syndrome; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Potassium Channels | 1990 |
A putative K(+)-selective channel in the plasma membrane of yeast that is blocked by micromolar concentrations of external divalent cations and is insensitive to tetraethylammonium.
Topics: 4-Aminopyridine; Amifampridine; Cations, Divalent; Cell Membrane; Glucose; Membrane Potentials; Potassium Channels; Saccharomyces cerevisiae; Tetraethylammonium Compounds | 1990 |
Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Amifampridine; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Multiple Sclerosis; Potassium Channels | 1990 |
Optical recording of epileptiform voltage changes in the neocortical slice.
Topics: 4-Aminopyridine; Amifampridine; Animals; Bicuculline; Cerebral Cortex; Convulsants; Electrophysiology; Epilepsy; Evoked Potentials; Guinea Pigs; In Vitro Techniques; Membrane Potentials | 1990 |
[Lambert-Eaton myasthenic syndrome].
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Antibodies, Antinuclear; Child; Electromyography; Female; Germine Acetates; Guanidine; Guanidines; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscles; Neuromuscular Junction | 1990 |
Potentiation of a transient outward current by Na+ influx in crayfish neurones.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Astacoidea; Egtazic Acid; Ion Channels; Motor Neurons; Ouabain; Sodium; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1985 |
Effects of 3,4-diaminopyridine and tetraethylammonium on the pre- and post-junctional alpha-adrenoceptor mediated inhibitory actions of noradrenaline in the guinea-pig ileum.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Atropine; Electric Stimulation; Female; Guinea Pigs; Ileum; In Vitro Techniques; Ion Channels; Male; Muscle Contraction; Muscle, Smooth; Neuromuscular Junction; Norepinephrine; Receptors, Adrenergic, alpha; Tetraethylammonium Compounds | 1985 |
Low-threshold, slow-inactivating Na+ potentials in the cockroach giant axon.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Axons; Calcium; Ion Channels; Male; Membrane Potentials; Periplaneta; Potassium; Sodium; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1985 |
A calcium-activated potassium current in motor nerve terminals of the mouse.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Barium; Calcium; Cobalt; In Vitro Techniques; Ion Channels; Manganese; Mice; Motor Endplate; Neuromuscular Junction; Potassium; Synaptic Transmission; Tetraethylammonium; Tetraethylammonium Compounds | 1985 |
Electrical activity of mouse motor endings during muscle reinnervation.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Ion Channels; Membrane Potentials; Mice; Motor Neurons; Nerve Regeneration; Potassium; Sodium; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1985 |
Two different presynaptic calcium currents in mouse motor nerve terminals.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Barium; Cadmium; Calcium; Diltiazem; In Vitro Techniques; Ion Channels; Kinetics; Manganese; Mice; Motor Neurons; Neuromuscular Junction; Potassium; Strontium; Synapses; Tetraethylammonium; Tetraethylammonium Compounds; Verapamil | 1986 |
Interaction of 4-aminopyridine with [3H]phencyclidine receptors in rat brain homogenates.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Binding, Competitive; Brain; Ion Channels; Male; Rats; Rats, Inbred Strains; Receptors, Neurotransmitter; Receptors, Phencyclidine; Synaptic Membranes | 1986 |
Dendrotoxin: a selective blocker of a non-inactivating potassium current in guinea-pig dorsal root ganglion neurones.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Elapid Venoms; Ganglia, Spinal; Guinea Pigs; In Vitro Techniques; Ion Channels; Membrane Potentials; Potassium; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1986 |
Phasic contractions of canine and human coronary arteries induced by potassium channel blockers.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Aminopyridines; Angina Pectoris, Variant; Animals; Arteries; Coronary Vasospasm; Coronary Vessels; Dogs; Female; Humans; Ion Channels; Macaca mulatta; Male; Middle Aged; Models, Biological; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nifedipine; Swine; Tetraethylammonium Compounds; Vasoconstriction | 1986 |
Potassium channel blockers and impulse propagation in murine motor endplate disease.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; In Vitro Techniques; Ion Channels; Mice; Mice, Inbred C3H; Motor Endplate; Neuromuscular Diseases; Neuromuscular Junction; Potassium; Tetraethylammonium; Tetraethylammonium Compounds | 1987 |
Characterization of the basolateral membrane conductance of Necturus urinary bladder.
Topics: 4-Aminopyridine; Amifampridine; Amiloride; Aminopyridines; Animals; Cell Membrane; Chlorides; Decamethonium Compounds; Electric Conductivity; Epithelium; Ion Channels; Male; Membrane Potentials; Necturus; Potassium; Seasons; Tetraethylammonium Compounds; Urinary Bladder; Water-Electrolyte Balance | 1987 |
[Effects of vasodilators on cyclic contraction induced by 3,4-diaminopyridine in isolated porcine coronary arteries].
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Angina Pectoris; Animals; Calcium; Coronary Vessels; Drug Interactions; Guanidines; In Vitro Techniques; Ion Channels; Periodicity; Pinacidil; Potassium; Swine; Vasodilator Agents | 1987 |
The actions of presynaptic snake toxins on membrane currents of mouse motor nerve terminals.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Apamin; Aprotinin; Calcium; In Vitro Techniques; Ion Channels; Mice; Motor Endplate; Neuromuscular Junction; Phospholipases A; Phospholipases A2; Potassium; Snake Venoms; Tetraethylammonium; Tetraethylammonium Compounds | 1987 |
The effects of nicorandil on phasic contractions of isolated canine coronary artery.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calmodulin; Coronary Vessels; Dogs; Ergonovine; In Vitro Techniques; Membrane Potentials; Muscle Contraction; Niacinamide; Nicorandil; Nifedipine; Nitroglycerin; Vasodilator Agents | 1987 |
Presynaptic K-channel blockade counteracts the depressant effect of adenosine in olfactory cortex.
Topics: 4-Aminopyridine; Adenosine; Amifampridine; Aminopyridines; Animals; Cerebral Cortex; Female; Guinea Pigs; Hippocampus; In Vitro Techniques; Ion Channels; Male; Olfactory Bulb; Olfactory Pathways; Potassium; Synapses | 1988 |
Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins.
Topics: 1-Methyl-3-isobutylxanthine; 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Ammonium Chloride; Animals; Botulinum Toxins; Calcium; Cholera Toxin; Colforsin; Female; Guanidine; Guanidines; In Vitro Techniques; Methylamines; Mice; Neuromuscular Junction; Neurotoxins; Tetanus Toxin; Theophylline | 1988 |
Effects of charybdotoxin, a blocker of Ca2+-activated K+ channels, on motor nerve terminals.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Apamin; Calcium; Charybdotoxin; In Vitro Techniques; Membrane Potentials; Mice; Motor Endplate; Neuromuscular Junction; Potassium Channels; Scorpion Venoms | 1988 |
Effect of some potassium channel blockers on contractile responses of the rabbit aorta.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Aorta, Thoracic; Apamin; Calcium Channel Blockers; Endothelium, Vascular; Female; In Vitro Techniques; Isradipine; Male; Muscle Contraction; Muscle, Smooth, Vascular; Oxadiazoles; Potassium Channels; Rabbits; Scorpion Venoms; Tetraethylammonium Compounds | 1989 |
Isoproterenol activates a chloride current, not the transient outward current, in rabbit ventricular myocytes.
Topics: 4-Aminopyridine; Amifampridine; Animals; Cells, Cultured; Chloride Channels; Chlorides; Heart; Heart Ventricles; Ion Channels; Isoproterenol; Kinetics; Membrane Potentials; Membrane Proteins; Rabbits; Ventricular Function | 1989 |
Release of acetylcholine from tissue slices of the rat nucleus basalis magnocellularis.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Calcium; Choline O-Acetyltransferase; In Vitro Techniques; Male; Potassium; Quinolinic Acid; Quinolinic Acids; Rats; Rats, Inbred Strains; Spinal Cord | 1989 |
Analysis of 3,4-diaminopyridine in human serum by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection.
Topics: 4-Aminopyridine; Adult; Amifampridine; Chromatography, High Pressure Liquid; Humans; Male; Middle Aged; Multiple Sclerosis; Potassium Channels; Spectrophotometry, Ultraviolet | 1989 |
Characterization of the actions of botulinum neurotoxin type E at the rat neuromuscular junction.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins; Electric Stimulation; Male; Neuromuscular Junction; Rats; Rats, Inbred Strains; Synaptic Transmission | 1989 |
Effects of cadmium on quantal transmitter release and ultrastructure of frog motor nerve endings.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Cadmium; Diaphragm; In Vitro Techniques; Male; Motor Neurons; Nerve Endings; Neurotransmitter Agents; Rana esculenta; Respiratory Muscles; Synaptic Transmission; Tetrodotoxin | 1989 |
3,4-Diaminopyridine-induced noradrenaline release from CNS tissue as a model for action potential-evoked transmitter release: effects of phorbol ester.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Brain; Enzyme Activation; Evoked Potentials; Hippocampus; In Vitro Techniques; Models, Biological; Neurotransmitter Agents; Norepinephrine; Phorbol Esters; Protein Kinase C; Rabbits | 1989 |
A study of synchronization of quantal transmitter release from mammalian motor endings by the use of botulinal toxins type A and D.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Botulinum Toxins; Female; Male; Mice; Motor Endplate; Neuromuscular Junction; Neurotransmitter Agents; Rats; Rats, Inbred Strains; Synaptic Transmission; Tetraethylammonium; Tetraethylammonium Compounds | 1989 |
Block of potassium channels and facilitation of acetylcholine release at the neuromuscular junction by the venom of the scorpion, Pandinus imperator.
Topics: 4-Aminopyridine; Acetylcholine; Action Potentials; Amifampridine; Aminopyridines; Animals; Chickens; Electrophysiology; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Motor Endplate; Muscle Contraction; Neuromuscular Junction; Potassium Channels; Scorpion Venoms; Stimulation, Chemical | 1989 |
Electrophysiological function of the delayed rectifier (IK) in bullfrog sympathetic ganglion neurones.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Barium; Calcium; Ganglia, Sympathetic; In Vitro Techniques; Neurons; Potassium Channels; Rana catesbeiana | 1989 |
Changes in cytosolic free calcium with 1,2,3,4-tetrahydro-5-aminoacridine, 4-aminopyridine and 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Amifampridine; Aminoacridines; Aminopyridines; Animals; Brain; Calcium; Cytosol; In Vitro Techniques; Mice; Synaptosomes; Tacrine | 1988 |
Differential effects of potassium channel blockers on neurohypophysial release of oxytocin and vasopressin. Evidence for frequency-dependent interaction with the endogenous opioid inhibition of oxytocin release.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Benzopyrans; Cromakalim; Electric Stimulation; Endorphins; Female; Naloxone; Oxytocin; Pituitary Gland, Posterior; Potassium Channels; Pyrroles; Radioimmunoassay; Rats; Rats, Inbred Strains; Tetraethylammonium; Tetraethylammonium Compounds; Vasopressins | 1988 |
A comparison of the antagonisms by neostigmine and diaminopyridine against the neuromuscular block caused by cobrotoxin and (+)-tubocurarine.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Antidotes; Cobra Neurotoxin Proteins; Diaphragm; Drug Synergism; Female; In Vitro Techniques; Male; Mice; Mice, Inbred ICR; Neostigmine; Neuromuscular Blocking Agents; Phrenic Nerve; Tubocurarine | 1986 |
Antagonism of non-depolarising neuromuscular blockade by aminopyridines in cats.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Androstane-3,17-diol; Animals; Cats; Male; Neuromuscular Nondepolarizing Agents; Pancuronium; Pipecuronium; Piperazines; Sciatic Nerve; Vecuronium Bromide | 1986 |
Effects of toxin II from the sea anemone Anemonia sulcata on contractile and electrical responses of frog skeletal muscle fibres.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Cnidarian Venoms; Formamides; In Vitro Techniques; Isometric Contraction; Membrane Potentials; Muscle Contraction; Muscles; Rana esculenta; Rana temporaria | 1986 |
Nicotinic antagonists produce differing amounts of tetanic fade in the isolated diaphragm of the rat.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Diaphragm; Electric Stimulation; Erabutoxins; Ganglionic Blockers; In Vitro Techniques; Male; Muscle Contraction; Neuromuscular Nondepolarizing Agents; Rats; Rats, Inbred Strains | 1986 |
Differential alteration of dopamine, acetylcholine, and glutamate release during anoxia and/or 3,4-diaminopyridine treatment.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Calcium; Corpus Striatum; Dopamine; Glutamates; Glutamic Acid; Hypoxia; In Vitro Techniques; Male; Mice; Potassium | 1987 |
The actions of phenol and pentachlorophenol (PCP) on axonal conduction, ganglionic synaptic transmission, and the effect of pH changes.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Anura; Axons; Chlorophenols; Ganglia; Hydrogen-Ion Concentration; In Vitro Techniques; Liver; Neural Conduction; Pentachlorophenol; Phenols; Procaine; Synapses | 1988 |
Three potassium currents in mouse motor nerve terminals.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Guanidines; Mice; Neuromuscular Junction; Organometallic Compounds; Potassium Channels; Tetraethylammonium Compounds | 1989 |
Effects of nicorandil on the rhythmic contractile response of isolated miniature pig coronary artery to 3,4-diaminopyridine: comparison with nitroglycerin.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Coronary Vasospasm; Coronary Vessels; Female; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nitroglycerin; Swine; Swine, Miniature | 1986 |
Neurotoxicity of quinolinate in the rat nucleus basalis magnocellularis.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Basal Ganglia; Cerebral Cortex; Choline O-Acetyltransferase; Cholinergic Fibers; Kainic Acid; Magnesium; Male; Microinjections; Neural Pathways; Picolinic Acids; Pyridines; Quinolinic Acid; Quinolinic Acids; Rats | 1987 |
Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Botulinum Toxins; Evoked Potentials; Imidoesters; Injections, Subcutaneous; Lethal Dose 50; Male; Mice; Motor Endplate; Muscle, Smooth; Neuromuscular Junction; Rats; Rats, Inbred Strains; Synaptic Transmission | 1985 |
Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electromyography; Humans; Male; Middle Aged; Myasthenia Gravis; Neuromuscular Junction; Pyridostigmine Bromide; Synaptic Transmission | 1985 |
Synaptic facilitation by 3-aminopyridine and its antagonism by verapamil and diltiazem.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Benzazepines; Calcium; Diltiazem; Dose-Response Relationship, Drug; Rana catesbeiana; Synapses; Synaptic Transmission; Verapamil | 1985 |
Equipotency of anti-curare activity of 4-aminopyridine and 3,4-diaminopyridine in anesthetized rats.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Anesthesia; Animals; In Vitro Techniques; Male; Muscle Contraction; Muscle Denervation; Neuromuscular Depolarizing Agents; Rats; Rats, Inbred Strains; Sciatic Nerve; Tubocurarine | 1985 |
A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Botulinum Toxins; Botulism; Dose-Response Relationship, Drug; In Vitro Techniques; Mice; Neuromuscular Junction; Paralysis; Rats; Synaptic Transmission; Tetanus Toxin | 1986 |
The effects of hemicholinium-3 (Hc-3) during tetanic (TP) and posttetanic potentiation (PTP) on sympathetic ganglion.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Anura; Calcium; Electric Stimulation; Electrophysiology; Ganglia, Sympathetic; Hemicholinium 3; Muscle Contraction; Synapses; Synaptic Transmission | 1986 |
Effect of mono- and diaminopyridines on release of [3H]norepinephrine from isolated guinea-pig atrium.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Cocaine; Electric Stimulation; Female; Guinea Pigs; Heart; In Vitro Techniques; Male; Myocardium; Norepinephrine | 1987 |
[Antagonism of the neuromuscular-blocking effect of polymyxin B by 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Female; Male; Muscle Contraction; Neuromuscular Blocking Agents; Phrenic Nerve; Polymyxin B; Polymyxins; Rats | 1987 |
Decreasing potassium conductance--a possible mechanism of phasic coronary vasospasm.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Coronary Vasospasm; Coronary Vessels; Dogs; Ergonovine; Female; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Macaca mulatta; Male; Membrane Potentials; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Myocardium; Niacinamide; Nicorandil; Nifedipine; Potassium; Swine; Tetraethylammonium; Tetraethylammonium Compounds | 1985 |
[Effects of 3,4-diaminopyridine on the contractions of guinea-pig tracheal smooth muscle induced by histamine and prostaglandin D2].
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Drug Synergism; Guinea Pigs; Histamine; In Vitro Techniques; Muscle Contraction; Muscle, Smooth; Nifedipine; Prostaglandin D2; Prostaglandins D; Tetrodotoxin; Trachea | 1988 |
The potassium conductance of the resting squid axon and its blockage by clinical concentrations of general anaesthetics.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Anesthetics; Animals; Axons; Decapodiformes; In Vitro Techniques; Membrane Potentials; Potassium Channels; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin; Time Factors | 1988 |
Presynaptic Na/Ca action potentials in unmyelinated axons of olfactory cortex.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Amygdala; Animals; Axons; Calcium; Calcium Channel Blockers; Cations, Divalent; Cerebral Cortex; Female; Guinea Pigs; In Vitro Techniques; Male; Potassium; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1988 |
Effects of adenosine and calcium entry blockers on 3,4-diaminopyridine-induced rhythmic contractions in dog coronary artery.
Topics: 4-Aminopyridine; Adenosine; Adenosine-5'-(N-ethylcarboxamide); Amifampridine; Aminopyridines; Animals; Calcium Channel Blockers; Diltiazem; Dogs; In Vitro Techniques; Muscle Contraction; Muscle, Smooth, Vascular; Phenylisopropyladenosine | 1988 |
Cholinergic nerve terminals in the ventrolateral medullary pressor area: pharmacological evidence.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Blood Pressure; Hemicholinium 3; Medulla Oblongata; Microinjections; Nerve Endings; Parasympathetic Nervous System; Pirenzepine; Receptors, Muscarinic; Scopolamine; Sympathetic Nervous System | 1988 |
Relation between action potential duration and mechanical activity on rat diaphragm fibers. Effects of 3,4-diaminopyridine and tetraethylammonium.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Caffeine; In Vitro Techniques; Muscle Contraction; Potassium; Rats; Rats, Inbred Strains; Respiratory Muscles; Tetraethylammonium Compounds | 1987 |
Ineffectiveness of 3,4-diaminopyridine as a therapy for type C botulism.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Botulism; Mice; Neuromuscular Junction | 1987 |
Effects of extracellular calcium and calcium channel blocker on silver-induced contractures in frog skeletal muscle fibers.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Calcium Channel Blockers; Diltiazem; Drug Interactions; Morpholines; Muscle Contraction; Rana catesbeiana; Silver; Solutions; Tetrodotoxin | 1987 |
Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin.
Topics: 4-Aminopyridine; Amifampridine; Aminoglycosides; Aminopyridines; Animals; Anti-Bacterial Agents; Botulinum Toxins; Kinetics; Male; Membrane Potentials; Microelectrodes; Motor Endplate; Neuromuscular Junction; Rana temporaria | 1987 |
Pre- and postsynaptic effects of nicotine on the mouse phrenic nerve-diaphragm preparation.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Diaphragm; Electric Stimulation; Female; In Vitro Techniques; Kinetics; Male; Membrane Potentials; Mice; Mice, Inbred ICR; Muscle Contraction; Muscles; Neostigmine; Neuromuscular Junction; Nicotine; Phrenic Nerve; Succinylcholine; Synapses; Tubocurarine | 1987 |
Angiographic and angioscopic observations of the arterial luminal changes induced by vasospasm.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Angiography; Animals; Carotid Artery Diseases; Dogs; Endoscopy; Female; Fiber Optic Technology; Male; Spasm | 1987 |
Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Botulinum Toxins; Botulism; Injections, Intraperitoneal; Lethal Dose 50; Male; Mice; Serotyping; Time Factors | 1986 |
Spontaneous excitatory postsynaptic currents in crayfish neuromuscular junctions in the absence and presence of serotonin and 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Astacoidea; Electric Stimulation; Evoked Potentials; Neuromuscular Junction; Serotonin; Synapses | 1986 |
Inhibition of 3,4-diaminopyridine-induced coronary oscillation by adenyl compounds.
Topics: 4-Aminopyridine; Adenine Nucleotides; Adenosine; Amifampridine; Aminophylline; Aminopyridines; Animals; Coronary Vessels; Dilazep; Dogs; Drug Interactions; In Vitro Techniques; Indomethacin; Membrane Potentials; Muscle, Smooth, Vascular | 1986 |
Diagnosis and treatment of botulism in lions.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Amoxicillin; Animals; Animals, Zoo; Botulinum Antitoxin; Botulinum Toxins; Botulism; Carnivora; Diagnosis, Differential; Diazepam; Female; Fluid Therapy; Lions; Male; Salmonella Infections, Animal | 1985 |
Subsynaptosomal calcium distribution during hypoxia and 3,4-diaminopyridine treatment.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Centrifugation; Digitonin; Hypoxia, Brain; Male; Membrane Potentials; Mice; Mitochondria; Potassium; Subcellular Fractions; Synaptosomes | 1985 |
Subsynaptosomal distribution of calcium during aging and 3,4-diaminopyridine treatment.
Topics: 4-Aminopyridine; Aging; Amifampridine; Aminopyridines; Animals; Brain; Calcium; Digitonin; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Mitochondria; Onium Compounds; Organophosphorus Compounds; Potassium; Synaptosomes | 1985 |
Slowly inactivating potassium channels induced in Xenopus oocytes by messenger ribonucleic acid from Torpedo brain.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Brain Chemistry; Electric Conductivity; Female; Ion Channels; Membrane Potentials; Oocytes; Potassium; RNA, Messenger; Tetraethylammonium; Tetraethylammonium Compounds; Time Factors; Torpedo; Xenopus laevis | 1984 |
Potentiation between neostigmine and 3,4-diaminopyridine in antagonizing the neuromuscular block induced by D-tubocurarine.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Drug Synergism; Female; Male; Mice; Muscle Contraction; Neostigmine; Nerve Block; Synaptic Transmission; Tubocurarine | 1984 |
Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Evoked Potentials; Female; Ion Channels; Microelectrodes; Motor Endplate; Neuromuscular Depolarizing Agents; Neuromuscular Junction; Neurotransmitter Agents; Potassium; Rats; Rats, Inbred Strains; Stimulation, Chemical; Synaptic Transmission | 1983 |
Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Botulinum Toxins; Dinitrophenols; Electric Stimulation; Evoked Potentials; Male; Motor Endplate; Neuromuscular Junction; Neurotransmitter Agents; Rats; Rats, Inbred Strains; Synaptic Transmission | 1983 |
Comparison of some pharmacological properties of 4-aminopyridine and 3,4-diaminopyridine in vivo.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Central Nervous System Stimulants; Depression, Chemical; Drug Interactions; Mice; Morphine; Respiration | 1984 |
The actions of 3,4-diaminopyridine in bullfrog sympathetic ganglia.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Axonal Transport; Ganglia, Sympathetic; Microelectrodes; Rana catesbeiana; Synapses; Tetraethylammonium; Tetraethylammonium Compounds; Tubocurarine | 1982 |
Effect of 3,4-diaminopyridine and tetraethylammonium on the presynaptic blockade caused by beta-bungarotoxin.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Bungarotoxins; Chickens; In Vitro Techniques; Mice; Neuromuscular Junction; Synapses; Synaptic Transmission; Tetraethylammonium Compounds | 1980 |
3,4-diaminopyridine alters acetylcholine metabolism and behavior during hypoxia.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Aminopyridines; Animals; Behavior, Animal; Brain; Calcium; Glucose; Homeostasis; Hypoxia; Ion Channels; Male; Mice; Oxygen; Potassium | 1982 |
Aminopyridine block of transient potassium current.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Electric Conductivity; In Vitro Techniques; Ion Channels; Membrane Potentials; Microelectrodes; Mollusca; Neural Inhibition; Neurons; Potassium | 1982 |
Electronic properties of motor nerve terminals.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Evoked Potentials; Membrane Potentials; Motor Endplate; Motor Neurons; Neuromuscular Junction; Rana temporaria; Synaptic Transmission; Tetraethylammonium Compounds; Tetrodotoxin | 1982 |
A comparison of 3,4-diaminopyridine and 4-aminopyridine in the anaesthetized cat.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Anesthesia; Animals; Blood Pressure; Cats; Female; Heart Rate; Male; Neuromuscular Junction; Nictitating Membrane; Synaptic Transmission | 1982 |
Effects of dithiothreitol, 5,5'-dithiobis(2-nitrobenzoic acid) and N-ethylmaleimide on synaptic transmission at sympathetic ganglion cells of frog.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Dithionitrobenzoic Acid; Dithiothreitol; Ethylmaleimide; Ganglia, Sympathetic; In Vitro Techniques; Microelectrodes; Nitrobenzoates; Rana catesbeiana; Synaptic Transmission | 1982 |
Effects of 3,4-diaminopyridine on mechanical and electrical responses of frog single muscle fibres.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; In Vitro Techniques; Ion Channels; Muscle Contraction; Muscles; Potassium; Rana temporaria; Tubocurarine | 1983 |
Site of action and active form of aminopyridines in squid axon membranes.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Axons; Calcium Channel Blockers; Decapodiformes; Electrophysiology; Ion Channels; Potassium; Structure-Activity Relationship | 1983 |
Calcium action potentials in rat fast-twitch and slow-twitch muscle fibres.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Barium; Calcium; Chlorides; Electric Conductivity; In Vitro Techniques; Ion Channels; Muscles; Nifedipine; Potassium; Rats; Rats, Inbred Strains; Tetraethylammonium Compounds; Time Factors | 1983 |
Kinetic properties of calcium channels of twitch muscle fibres of the frog.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; In Vitro Techniques; Ion Channels; Kinetics; Membrane Potentials; Muscles; Potassium; Rana temporaria; Tetraethylammonium; Tetraethylammonium Compounds | 1983 |
Novel drug of choice in Eaton-Lambert syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Female; Humans; Middle Aged; Myasthenia Gravis; Neuromuscular Junction; Synaptic Transmission | 1983 |
Synaptic transmission in low extracellular calcium is preserved by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Calcium; Dose-Response Relationship, Drug; Extracellular Space; Ganglia, Sympathetic; In Vitro Techniques; Rana catesbeiana; Receptors, Neurotransmitter; Synapses | 1983 |
Synaptic facilitatory and depressant actions of 3,4-diaminopyridine: correlation with anticurare properties.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Curare; Dose-Response Relationship, Drug; Female; Ganglia, Sympathetic; In Vitro Techniques; Male; Rana catesbeiana; Synapses; Synaptic Transmission; Tubocurarine | 1983 |
Actions of potassium channel blockers on guinea-pig lateral olfactory tract axons.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Axons; Barium; Central Nervous System; Cesium; Electric Stimulation; Female; Guinea Pigs; In Vitro Techniques; Ion Channels; Olfactory Pathways; Potassium; Sparteine; Synapses | 1984 |
Presynaptic currents in frog motor endings.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Electric Conductivity; Ion Channels; Motor Neurons; Nerve Endings; Rana esculenta; Synapses; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1984 |
High-performance liquid chromatographic determination of 3,4-diaminopyridine in human plasma.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Chromatography, High Pressure Liquid; Humans | 1984 |
The effects of aminopyridines on the cortical evoked potentials.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Cats; Cerebral Cortex; Evoked Potentials, Somatosensory; Female; Male; Seizures | 1984 |
Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Autoimmune Diseases; Female; Humans; Middle Aged; Myasthenia Gravis; Pyridostigmine Bromide; Syndrome | 1984 |
Improvement of 8-arm maze performance in aged Fischer 344 rats with 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aging; Amifampridine; Aminopyridines; Animals; Male; Memory, Short-Term; Rats | 1983 |
The effect of some new aminopyridines on mammalian non-myelinated nerve fibres.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Biological Transport, Active; Guinea Pigs; In Vitro Techniques; Nerve Fibers; Sodium; Vagus Nerve | 1983 |
[Antagonistic effects of neostigmine, 4-aminopyridine and 3,4-diaminopyridine on muscle relaxing effects of d-tubocurarine].
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Muscle Contraction; Muscle Relaxation; Neostigmine; Neuromuscular Depolarizing Agents; Rats; Tubocurarine | 1983 |
Synaptosomal calcium metabolism during hypoxia and 3,4-diaminopyridine treatment.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Calcium; Hypoxia; Male; Mice; Synaptosomes | 1984 |
Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Injections, Intravenous; Injections, Intraventricular; Male; Rats; Rats, Inbred Strains; Seizures | 1984 |
Extracellular ions and excitation-contraction coupling in frog twitch muscle fibres.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Aminopyridines; Animals; Arsenazo III; Calcium; Chlorides; In Vitro Techniques; Muscle Contraction; Muscles; Potassium; Sarcoplasmic Reticulum; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1984 |
High-performance liquid chromatographic determination of 4-aminopyridine and 3,4-diaminopyridine in rat cerebrospinal fluid and serum.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Rats | 1983 |
Amelioration of age-related neurochemical and behavioral deficits by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Acetylcholine; Aging; Amifampridine; Aminopyridines; Animals; Behavior, Animal; Male; Mice; Mice, Inbred BALB C; Nervous System | 1983 |
The effects of 3,4-diaminopyridine on acetylcholine release at the frog neuromuscular junction.
Topics: 4-Aminopyridine; Acetylcholine; Action Potentials; Amifampridine; Aminopyridines; Animals; Calcium; Dose-Response Relationship, Drug; In Vitro Techniques; Neuromuscular Junction; Rana temporaria; Time Factors; Vinblastine | 1980 |
Serotonin and acetylcholine: further analysis of praziquantel-induced contraction of magnesium-paralysed Schistosoma mansoni.
Topics: 1-Methyl-3-isobutylxanthine; 4-Aminopyridine; Amifampridine; Animals; Arecoline; Carbachol; Colforsin; Dose-Response Relationship, Drug; In Vitro Techniques; Ions; Magnesium; Male; Muscle Contraction; Paralysis; Phorbol 12,13-Dibutyrate; Praziquantel; Schistosoma mansoni; Serotonin | 1993 |
Axolemmal and septal conduction in the impedance of the earthworm medial giant nerve fiber.
Topics: 4-Aminopyridine; Amifampridine; Animals; Axons; Electric Stimulation; In Vitro Techniques; Ion Channels; Membrane Potentials; Models, Neurological; Models, Theoretical; Nerve Fibers; Neural Conduction; Oligochaeta; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin | 1994 |
Origin of delayed outward ionic current in charge movement traces from frog skeletal muscle.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4-Aminopyridine; Amifampridine; Animals; Anions; Calcium; Cesium; Chloride Channels; Egtazic Acid; Furosemide; Gluconates; Glutamic Acid; Ion Channels; Muscle, Skeletal; Rana temporaria; Rubidium; Tetradecanoylphorbol Acetate; Tetrodotoxin; Time Factors | 1994 |
3,4-Diaminopyridine and choline increase in vivo acetylcholine release in rat striatum.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Animals; Choline; Corpus Striatum; Dose-Response Relationship, Drug; Drug Combinations; Male; Microdialysis; Rats; Rats, Sprague-Dawley | 1995 |
3,4-Diaminopyridine induced hydrolysis of phosphoinositide in cultured neurons from embryo chick forebrain.
Topics: 4-Aminopyridine; Amifampridine; Animals; Cells, Cultured; Chick Embryo; Culture Media; Hydrolysis; Membrane Potentials; Neurons; Phosphatidylinositols; Potassium; Potassium Channels; Prosencephalon | 1995 |
Regulation of membrane potential and diameter by voltage-dependent K+ channels in rabbit myogenic cerebral arteries.
Topics: 4-Aminopyridine; Amifampridine; Animals; Blood Pressure; Cerebral Arteries; Electrophysiology; Membrane Potentials; Muscle Tonus; Muscle, Smooth, Vascular; Potassium Channel Blockers; Potassium Channels; Rabbits; Vasoconstriction | 1995 |
3,4-Diaminopyridine facilitates norepinephrine release in chick sympathetic neurons.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channel Blockers; Calcium Channels; Chick Embryo; Ganglia, Sympathetic; Neurons; Norepinephrine; omega-Conotoxin GVIA; Peptides; Tetrodotoxin | 1995 |
Determination of 3,4-diaminopyridine in human plasma by high-performance liquid chromatography.
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Calibration; Chromatography, High Pressure Liquid; Dosage Forms; Humans; Reference Standards; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 1995 |
Physostigmine, but not 3,4-diaminopyridine, improves radial maze performance in memory-impaired rats.
Topics: 4-Aminopyridine; Amifampridine; Animals; Cerebral Cortex; Choline O-Acetyltransferase; Dose-Response Relationship, Drug; Male; Maze Learning; Memory Disorders; Memory, Short-Term; Physostigmine; Potassium Channels; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Scopolamine | 1995 |
Antianginal effects of YM-16151-4 in various experimental angina models.
Topics: 4-Aminopyridine; Amifampridine; Angina Pectoris; Animals; Arginine Vasopressin; Atrioventricular Node; Calcium Channel Blockers; Coronary Circulation; Coronary Vasospasm; Dihydropyridines; Dogs; Electrocardiography; Female; Heart Conduction System; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nifedipine; Nitrophenols; Oxygen Consumption; Potassium Channels; Propranolol | 1993 |
Involvement of nitric oxide synthase in 3,4-diaminopyridine-evoked noradrenaline release in rat hippocampus.
Topics: 4-Aminopyridine; Amifampridine; Amino Acid Oxidoreductases; Animals; Arginine; Electric Stimulation; Hippocampus; In Vitro Techniques; Nitric Oxide Synthase; Norepinephrine; Potassium Channels; Rats; Signal Transduction | 1993 |
3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis.
Topics: 4-Aminopyridine; Affect; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cognition; Female; Humans; Male; Middle Aged; Movement; Neural Conduction | 1995 |
Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Female; Heart Arrest; Humans; Iatrogenic Disease; Lambert-Eaton Myasthenic Syndrome | 1995 |
[Lithium-induced norepinephrine release from hippocampal slices in the absence of extracellular Ca2+].
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Drug Synergism; Hippocampus; In Vitro Techniques; Lithium; Male; Norepinephrine; Phorbol 12,13-Dibutyrate; Rats; Rats, Sprague-Dawley; Tetrodotoxin | 1994 |
[Therapy of experimental autoimmune myasthenia gravis in rabbits with 4-aminopyridine and 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Female; Male; Myasthenia Gravis; Rabbits | 1994 |
Verapamil toxicity.
Topics: 4-Aminopyridine; Amifampridine; Animals; Poisoning; Swine; Verapamil | 1995 |
Vasospasmolytic effect of KRN2391 on 3,4-diaminopyridine-induced rhythmic contraction of porcine coronary artery.
Topics: 4-Aminopyridine; Amifampridine; Animals; Benzopyrans; Coronary Vessels; Cromakalim; In Vitro Techniques; Ion Channel Gating; Nitroglycerin; Potassium Channels; Pyridines; Pyrroles; Swine; Vasoconstriction; Vasodilator Agents | 1994 |
[Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Aged; Amifampridine; Carcinoma, Small Cell; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Potassium Channels; Remission Induction | 1995 |
Membrane events related to transmitter release in mouse motor nerve terminals captured by ultrarapid cryofixation.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Animals; Electric Stimulation; Fixatives; Freezing; Hydrolyzable Tannins; Male; Mice; Microscopy, Electron; Motor Endplate; Neurotransmitter Agents; Potassium; Synaptic Vesicles; Tubocurarine | 1993 |
Interactions between suxamethonium and non-depolarizing neuromuscular blocking drugs.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Cats; Drug Interactions; Female; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Muscle Contraction; Neuromuscular Nondepolarizing Agents; Succinylcholine; Tetraethylammonium; Tetraethylammonium Compounds; Time Factors; Tubocurarine; Vecuronium Bromide | 1994 |
Studies on the role of K+, Cl- and Na+ ion permeabilities in the acetylcholine release enhancing effects of linopirdine (DuP 996) in rat cortical slices.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4-Aminopyridine; Acetylcholine; Amifampridine; Animals; Cerebral Cortex; Chlorides; In Vitro Techniques; Indoles; Male; Permeability; Potassium; Pyridines; Rats; Rats, Wistar; Sodium; Tetraethylammonium Compounds; Tetrodotoxin | 1994 |
External Ca(2+)-independent norepinephrine release from hippocampal slices and modulation by protein kinase C activation.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Hippocampus; Male; Monensin; Norepinephrine; Ouabain; Phorbol 12,13-Dibutyrate; Potassium Channels; Protein Kinase C; Rats; Veratridine | 1994 |
The use of potassium channel blocking agents in the therapy of demyelinating diseases.
Topics: 4-Aminopyridine; Amifampridine; Demyelinating Diseases; Humans; Potassium Channels | 1994 |
Effects of 3,4-diaminopyridine on myoplasmic calcium and phosphoinositide hydrolysis in frog sartorius muscle fibers.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Dose-Response Relationship, Drug; Hydrolysis; Muscles; Phosphatidylinositols; Potassium Channels; Ranidae | 1994 |
Zinc ions block rectifier potassium channels and calcium activated potassium channels at the frog motor nerve endings.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Edetic Acid; In Vitro Techniques; Motor Neurons; Muscles; Neuromuscular Junction; Potassium Channels; Rana pipiens; Skin; Tetraethylammonium; Tetraethylammonium Compounds; Time Factors; Zinc | 1994 |
Effect of pre-treating rat atria with potassium channel blocking drugs on the electrical and mechanical responses to phenylephrine.
Topics: 4-Aminopyridine; Action Potentials; Adenosine; Amantadine; Amifampridine; Animals; Cesium; Chlorides; Heart Atria; In Vitro Techniques; Isoproterenol; Phenylephrine; Potassium Channel Blockers; Rats; Sparteine; Systole | 1994 |
3,4-Diaminopyridine in demyelinating peripheral neuropathies.
Topics: 4-Aminopyridine; Amifampridine; Demyelinating Diseases; Humans; Neural Conduction; Potassium Channels | 1994 |
Kinetic basis for the voltage-dependent inhibition of N-type calcium current by somatostatin and norepinephrine in chick sympathetic neurons.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channel Blockers; Calcium Channels; Cells, Cultured; Cesium; Chick Embryo; Electric Stimulation; Ganglia, Sympathetic; GTP-Binding Proteins; Kinetics; Membrane Potentials; Neurons; Norepinephrine; omega-Conotoxins; Peptides; Pertussis Toxin; Second Messenger Systems; Somatostatin; Tetraethylammonium; Tetraethylammonium Compounds; Tetrodotoxin; Time Factors; Virulence Factors, Bordetella | 1993 |
Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity.
Topics: 4-Aminopyridine; Amifampridine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hemodynamics; Poisoning; Potassium Channels; Swine; Verapamil | 1994 |
A 3,4-diaminopyridine-insensitive, Ca(2+)-independent transient outward K+ current in cardiac ventricular myocytes.
Topics: 4-Aminopyridine; Amifampridine; Animals; Barium; Calcium; Cats; Cesium; Electric Conductivity; Intracellular Membranes; Kinetics; Magnesium; Myocardium; Osmolar Concentration; Potassium; Potassium Channel Blockers; Sodium; Ventricular Function | 1994 |
Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy.
Topics: 4-Aminopyridine; Action Potentials; Adult; Amifampridine; Combined Modality Therapy; Electric Stimulation; Electromyography; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Movement; Plasma Exchange | 1994 |
Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Clinical Protocols; Drug Synergism; Drug Therapy, Combination; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscles; Neoplasms; Parasympathomimetics; Pyridostigmine Bromide | 1993 |
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
Topics: 4-Aminopyridine; Amifampridine; Animals; Antihypertensive Agents; Biomechanical Phenomena; Glyburide; Guanidines; Hypertension; Male; Molecular Structure; Norbornanes; Pinacidil; Portal Vein; Potassium Channels; Rats; Rats, Inbred SHR; Rats, Wistar; Structure-Activity Relationship | 1994 |
Potassium channel antagonists and vascular reactivity in stroke-prone spontaneously hypertensive rats.
Topics: 4-Aminopyridine; Amifampridine; Animals; Apamin; Barium; Cardiovascular System; Carotid Arteries; Cell Membrane; Cerebrovascular Disorders; Diazoxide; Female; Glyburide; Hypertension; Male; Muscle, Smooth, Vascular; Potassium Channels; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Risk Factors; Tetraethylammonium; Tetraethylammonium Compounds; Vasoconstriction; Vasodilation | 1993 |
Action of alpha-dendrotoxin on K+ currents in nerve terminal regions of axons in rat olfactory cortex.
Topics: 4-Aminopyridine; Amifampridine; Animals; Axons; Cadmium; Cerebral Cortex; Elapid Venoms; Female; In Vitro Techniques; Myelin Sheath; Nerve Endings; Neurotoxins; Olfactory Bulb; Potassium Channels; Rats; Rats, Wistar; Sodium; Tetraethylammonium Compounds | 1993 |
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies.
Topics: 4-Aminopyridine; Amifampridine; Chronic Disease; Demyelinating Diseases; Humans; Neural Conduction; Polyradiculoneuropathy; Potassium Channels; Time Factors | 1993 |
[The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Carcinoma, Small Cell; Drug Evaluation; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged | 1993 |
Voltage-dependent calcium and potassium conductances in striated muscle fibers from the scorpion, Centruroides sculpturatus.
Topics: 4-Aminopyridine; Amifampridine; Animals; Barium; Calcium; Calcium Channels; Cell Membrane; Electric Stimulation; Ion Channel Gating; Membrane Potentials; Microelectrodes; Muscle Contraction; Muscles; Potassium; Potassium Channels; Scorpions; Tetraethylammonium; Tetraethylammonium Compounds; Time Factors | 1993 |
Loss of vasoreactivity by laser thermal energy or argon laser irradiation.
Topics: 4-Aminopyridine; Amifampridine; Angioplasty, Laser; Animals; Coronary Angiography; Coronary Vasospasm; Coronary Vessels; Dogs; Hyperthermia, Induced; In Vitro Techniques; Potassium; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 1993 |
[3,4-Diaminopyridine-evoked norepinephrine release and B-50 (GAP-43) phosphorylation].
Topics: 4-Aminopyridine; Amifampridine; Animals; GAP-43 Protein; Hippocampus; Male; Membrane Glycoproteins; Nerve Tissue Proteins; Norepinephrine; Phorbol 12,13-Dibutyrate; Phosphorylation; Polymyxin B; Potassium Channels; Rats; Rats, Sprague-Dawley | 1993 |
3,4-Diaminopyridine-evoked noradrenaline release in rat hippocampal slices: facilitation by endogenous or exogenous nitric oxide.
Topics: 4-Aminopyridine; Amifampridine; Animals; Arginine; Cyclic GMP; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Hemoglobins; Hippocampus; In Vitro Techniques; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Norepinephrine; Perfusion; Rats; Synaptosomes | 1995 |
Ionic currents and inhibitory effects of glibenclamide in seminal vesicle smooth muscle cells.
Topics: 4-Aminopyridine; Amifampridine; Animals; Barium; Biological Transport, Active; Cadmium; Calcium; Calcium Channels; Egtazic Acid; Electric Stimulation; Glyburide; Guinea Pigs; Hypoglycemic Agents; Ion Transport; Male; Muscle Contraction; Muscle, Smooth; Norepinephrine; Patch-Clamp Techniques; Potassium; Potassium Channels; Potassium Chloride; Seminal Vesicles; Tetraethylammonium; Tetraethylammonium Compounds | 1995 |
Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins; Drug Interactions; Male; Muscle, Skeletal; Paralysis; Potassium Channel Blockers; Pyridostigmine Bromide; Rats; Rats, Inbred F344 | 1996 |
Toosendanin facilitates [3H]noradrenaline release from rat hippocampal slices.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Chelating Agents; Dantrolene; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Egtazic Acid; Hippocampus; In Vitro Techniques; Isotope Labeling; Muscle Relaxants, Central; Neuromuscular Blocking Agents; Norepinephrine; Potassium Channels; Rats; Rats, Sprague-Dawley; Reserpine; Sympatholytics; Tritium | 1996 |
[3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Potassium Channels; Time Factors | 1996 |
3,4-Diaminopyridine masks the inhibition of noradrenaline release from chick sympathetic neurons via presynaptic alpha 2-adrenoceptors: insights into the role of N- and L-type calcium channels.
Topics: 4-Aminopyridine; Adrenergic alpha-Agonists; Amifampridine; Animals; Brimonidine Tartrate; Calcium Channels; Cells, Cultured; Chick Embryo; Electric Stimulation; Fluorescent Dyes; Fluorometry; Fura-2; Neurons; Norepinephrine; Potassium Channels; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Presynaptic; Sympathetic Nervous System | 1996 |
Activity-dependent modulation of the presynaptic potassium current in the frog neuromuscular junction.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Axons; Computer Simulation; Electric Stimulation; In Vitro Techniques; Ion Transport; Kinetics; Models, Neurological; Neural Conduction; Neuromuscular Junction; Potassium; Potassium Channel Blockers; Potassium Channels; Presynaptic Terminals; Ranidae; Sodium | 1996 |
Effects of DAP on diaphragm force and fatigue, including fatigue due to neurotransmission failure.
Topics: 4-Aminopyridine; Amifampridine; Animals; Diaphragm; Electric Stimulation; In Vitro Techniques; Isometric Contraction; Male; Muscle Fatigue; Phrenic Nerve; Potassium Channels; Rats; Rats, Sprague-Dawley; Synaptic Transmission | 1996 |
Properties of 3,4-diaminopyridine-evoked dopamine and acetylcholine release in rabbit caudate nucleus slices: involvement of facilitatory adenosine A2 receptors or nitric oxide?
Topics: 4-Aminopyridine; Acetylcholine; Adenylyl Cyclases; Amifampridine; Animals; Caudate Nucleus; Dopamine; Dopamine Agents; Guanylate Cyclase; In Vitro Techniques; Neurotransmitter Agents; Nitric Oxide; Potassium Channels; Rabbits; Receptors, Purinergic P1; Stimulation, Chemical | 1996 |
Spasmolytic effect of efonidipine hydrochloride in isolated canine coronary artery: comparison with the effects of nifedipine and nisoldipine.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 4-Aminopyridine; Amifampridine; Animals; Arteries; Calcium Channel Blockers; Coronary Vessels; Dihydropyridines; Dogs; In Vitro Techniques; Nitrophenols; Organophosphorus Compounds; Potassium; Prostaglandin Endoperoxides, Synthetic; Thromboxane A2; Vasoconstrictor Agents | 1997 |
Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Amifampridine; Electromyography; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Motor Endplate; Time Factors | 1997 |
Effect of 4-aminopyridine and 3,4-diaminopyridine on guinea-pig isolated ileum.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Animals; Atropine; Calcium Channel Blockers; Diazoxide; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Female; Flunarizine; Guinea Pigs; Ileum; In Vitro Techniques; Lanthanum; Male; Muscle Contraction; Muscle, Smooth; Nifedipine; Parasympathetic Nervous System; Parasympatholytics; Potassium Channels; Vasodilator Agents; Verapamil | 1997 |
Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.
Topics: 4-Aminopyridine; Amifampridine; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; HeLa Cells; Humans; PC12 Cells; Physostigmine; Rats; Tacrine; Trichlorfon; Tumor Cells, Cultured | 1997 |
Antianginal effects of YM430, a novel calcium entry-blocking and beta-adrenoceptor-blocking agent in several experimental angina models.
Topics: 4-Aminopyridine; Adrenergic beta-Antagonists; Amifampridine; Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Disease; Coronary Vasospasm; Coronary Vessels; Dogs; Electrocardiography; Female; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Ischemia; Nifedipine; Propranolol; Rats | 1997 |
In permeabilised endothelial cells IP3-induced Ca2+ release is dependent on the cytoplasmic concentration of monovalent cations.
Topics: 4-Aminopyridine; Amifampridine; Aminacrine; Animals; Aorta; Calcium; Cations; Cattle; Cells, Cultured; Cobalt; Cytoplasm; Endothelium, Vascular; Inositol 1,4,5-Trisphosphate; Meglumine; Membrane Potentials; Potassium; Potassium Channel Blockers; Tetraethylammonium | 1998 |
3,4-Diaminopyridine-induced impairment in frog motor nerve terminal response to high frequency stimulation.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Electric Conductivity; Electric Stimulation; Motor Neurons; Neuromuscular Junction; Potassium; Presynaptic Terminals; Ranidae; Refractory Period, Electrophysiological; Sodium | 1998 |
An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Amifampridine; Analysis of Variance; Case-Control Studies; Electromyography; Evoked Potentials, Motor; Exercise Test; Fatigue; Female; Humans; Magnetics; Male; Multiple Sclerosis; Potassium Channels | 1998 |
Reduction of 3,4-diaminopyridine-induced biogenic amine synthesis and release in rat brain by gabapentin.
Topics: 4-Aminopyridine; 5-Hydroxytryptophan; Acetates; Amifampridine; Amines; Animals; Anticonvulsants; Biogenic Monoamines; Brain; Cyclohexanecarboxylic Acids; Dihydroxyphenylalanine; Dopamine; Gabapentin; gamma-Aminobutyric Acid; Male; Rats; Rats, Sprague-Dawley | 1998 |
Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Electromyography; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Muscle Fibers, Skeletal; Potassium Channel Blockers | 1998 |
3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Animals; Follow-Up Studies; Humans; Lambert-Eaton Myasthenic Syndrome; Mice; Myasthenia Gravis; Potassium Channels; Time Factors | 1998 |
A treatment algorithm for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Algorithms; Amifampridine; Azathioprine; Carcinoma, Small Cell; Clinical Protocols; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Potassium Channels; Prednisolone | 1998 |
Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Autoantibodies; Carcinoma, Small Cell; Child; Cholinesterase Inhibitors; Electrodiagnosis; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Plasmapheresis; Pyridostigmine Bromide; Receptors, Cholinergic | 1998 |
Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Female; Guanidine; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Parasympathomimetics; Potassium Channel Blockers; Pyridostigmine Bromide; Retrospective Studies; Thyroid Neoplasms | 1998 |
Functions of large conductance Ca2+-activated (BKCa), delayed rectifier (KV) and background K+ channels in the control of membrane potential in rabbit renal arcuate artery.
Topics: 4-Aminopyridine; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Amifampridine; Animals; Apamin; Arteries; Barium; Charybdotoxin; Glyburide; In Vitro Techniques; Kidney; Large-Conductance Calcium-Activated Potassium Channels; Male; Membrane Potentials; Muscle, Smooth, Vascular; Ouabain; Peptides; Potassium Channels; Potassium Channels, Calcium-Activated; Rabbits; Scorpion Venoms; Vasoconstriction | 1998 |
Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Diagnosis, Differential; Electric Stimulation; Electrodiagnosis; Evoked Potentials, Motor; Female; Humans; Isometric Contraction; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle, Skeletal; Peripheral Nerves | 1998 |
Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Female; Fingers; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Contraction; Muscle, Skeletal; Reaction Time | 1998 |
Electrophysiologic and inotropic effects of K+-channel blockade in aged diaphragm.
Topics: 4-Aminopyridine; Action Potentials; Adenosine Triphosphate; Aging; Amifampridine; Analysis of Variance; Animals; Chloride Channels; Diaphragm; Isometric Contraction; Male; Membrane Potentials; Muscle Contraction; Muscle, Skeletal; Potassium Channel Blockers; Rats; Rats, Inbred F344; Reaction Time | 1998 |
Successful treatment of peripheral paraneoplastic neurological syndromes in small cell cancer.
Topics: 4-Aminopyridine; Aged; Amifampridine; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Paraneoplastic Syndromes; Peripheral Nervous System Neoplasms | 1998 |
Involvement of intracellular Ca2+ stores in 3,4-diaminopyridine-evoked [3H]norepinephrine release.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Chelating Agents; Desipramine; Egtazic Acid; Hippocampus; In Vitro Techniques; Male; Norepinephrine; Rats; Rats, Sprague-Dawley; Reserpine | 1996 |
Role of K+ channels in A2A adenosine receptor-mediated dilation of the pressurized renal arcuate artery.
Topics: 4-Aminopyridine; Adenosine; Amifampridine; Animals; Antihypertensive Agents; Apamin; Arteries; Barium; Cromakalim; Enzyme Inhibitors; Glyburide; In Vitro Techniques; Kidney; Male; Nicardipine; Ouabain; Peptides; Phenethylamines; Potassium; Potassium Channels; Pressure; Purinergic P1 Receptor Agonists; Rabbits; Receptor, Adenosine A2A; Receptors, Purinergic P1; Vasodilation; Vasodilator Agents | 1999 |
The influence of phenylephrine outward potassium currents in single smooth muscle cells from the rabbit mesenteric artery.
Topics: 4-Aminopyridine; Adrenergic alpha-Antagonists; Amifampridine; Animals; Caffeine; Calcium; Chelating Agents; Drug Interactions; Egtazic Acid; Female; In Vitro Techniques; Membrane Potentials; Mesenteric Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Potassium; Potassium Channels; Prazosin; Rabbits; Tetraethylammonium; Vasoconstrictor Agents | 1999 |
Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins, Type A; Drug Delivery Systems; Hindlimb; Infusion Pumps, Implantable; Male; Muscle Contraction; Muscle, Skeletal; Organ Size; Paralysis; Potassium Channel Blockers; Rats | 2000 |
Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Aged, 80 and over; Amifampridine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Electrodiagnosis; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Potassium Channels | 2000 |
The effects of some K(+) channel blockers on scopolamine- or electroconvulsive shock-induced amnesia in mice.
Topics: 4-Aminopyridine; Amifampridine; Amnesia; Animals; Apamin; Avoidance Learning; Electroshock; Male; Mice; Muscarinic Antagonists; Potassium Channel Blockers; Retention, Psychology; Scopolamine | 2000 |
Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Electromyography; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Urinary Bladder, Neurogenic | 2001 |
Development and validation of a capillary electrophoresis assay for the determination of 3,4-diaminopyridine and 4-aminopyridine including related substances.
Topics: 4-Aminopyridine; Amifampridine; Electrophoresis, Capillary; Reproducibility of Results; Sensitivity and Specificity | 2001 |
Validation of a CE assay for the analysis of isomeric aminopyridines and diaminopyridines.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Electrophoresis, Capillary; Isomerism; Reproducibility of Results; Sensitivity and Specificity | 2001 |
Expression and function of native potassium channel [K(V)alpha1] subunits in terminal arterioles of rabbit.
Topics: 4-Aminopyridine; Amifampridine; Animals; Arterioles; Cell Membrane; Cerebrovascular Circulation; Delayed Rectifier Potassium Channels; Electric Conductivity; Endothelium, Vascular; Kv1.2 Potassium Channel; Kv1.5 Potassium Channel; Male; Muscle, Smooth, Vascular; Oocytes; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Rabbits; Scorpion Venoms; Tissue Distribution; Triterpenes; Xenopus laevis | 2001 |
[Quantitative evaluation of the effect of 3,4-diaminopyridine in a patient with Lambert-Eaton myasthenic syndrome using dynamic dynamometry].
Topics: 4-Aminopyridine; Action Potentials; Aged; Amifampridine; Electrophysiology; Female; Humans; Knee; Lambert-Eaton Myasthenic Syndrome; Movement; Muscle, Skeletal; Thigh; Treatment Outcome | 2001 |
[Treatment of severe botulism with 3,4-diaminopyridine]].
Topics: 4-Aminopyridine; Acetylcholine; Aged; Amifampridine; Botulinum Toxins; Botulinum Toxins, Type A; Botulism; Female; Foodborne Diseases; Humans; Neuromuscular Junction; Treatment Outcome | 2002 |
Improvement of dy/dy dystrophic diaphragm by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Amifampridine; Animals; Diaphragm; Disease Models, Animal; Electric Stimulation; Homozygote; In Vitro Techniques; Isometric Contraction; Laminin; Male; Mice; Muscle Contraction; Muscle Fatigue; Muscular Dystrophy, Animal; Potassium Channel Blockers; Stress, Mechanical; Time Factors | 2002 |
Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods.
Topics: 4-Aminopyridine; Acrylic Resins; Amifampridine; Delayed-Action Preparations; Drug Compounding; Excipients; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polyesters; Solvents | 2002 |
Raphé grafts and 3,4-diaminopyridine-evoked overflow of serotonin in the rat hippocampus after 5,7-dihydroxytryptamine lesions: evidence for 5-HT1A autoreceptors.
Topics: 4-Aminopyridine; 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Amifampridine; Animals; Autoreceptors; Brain Tissue Transplantation; Calcium; Calcium Signaling; Cells, Cultured; Denervation; Fetus; Hippocampus; Male; Neurons; Neurotoxins; Organ Culture Techniques; Potassium Channel Blockers; Raphe Nuclei; Rats; Rats, Long-Evans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Receptor Agonists; Tetrodotoxin | 2002 |
Membrane properties related to the firing behavior of zebrafish motoneurons.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Anesthetics, Local; Animals; Calcium Channels; Cobalt; Motor Neurons; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels; Sodium Channels; Swimming; Tetraethylammonium; Tetrodotoxin; Zebrafish | 2003 |
The vascular response to the K+ channel inhibitor 4-aminopyridine in hypertensive rats.
Topics: 4-Aminopyridine; Adrenalectomy; Adrenergic Antagonists; Amifampridine; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Endothelin Receptor Antagonists; Enzyme Inhibitors; Hypertension; In Vitro Techniques; Indomethacin; Losartan; Male; Muscarinic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phentolamine; Potassium Channel Blockers; Prazosin; Protein Kinase C; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Staurosporine; Sulfonamides; Vascular Resistance; Vasoconstriction | 2003 |
Wheel-running exercise alters rat diaphragm action potentials and their regulation by K+ channels.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Diaphragm; Male; Motor Activity; Muscle Contraction; Physical Endurance; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Sprague-Dawley | 2003 |
Streptozotocin-diabetes alters action potentials in rat diaphragm.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Diabetes Mellitus, Experimental; Diaphragm; Electrophysiology; Male; Microelectrodes; Organ Culture Techniques; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Wistar | 2003 |
Sternohyoid muscle fatigue properties of dy/dy dystrophic mice, an animal model of merosin-deficient congenital muscular dystrophy.
Topics: 4-Aminopyridine; Amifampridine; Animals; Disease Models, Animal; Electric Stimulation; Humans; In Vitro Techniques; Laminin; Male; Mice; Mice, Mutant Strains; Muscle Contraction; Muscle Fatigue; Muscular Dystrophies; Muscular Dystrophy, Animal; Neck Muscles; Potassium Channel Blockers | 2003 |
Potassium channels, the cerebellum, and treatment for downbeat nystagmus.
Topics: 4-Aminopyridine; Amifampridine; Humans; Models, Neurological; Nystagmus, Pathologic; Potassium Channel Blockers; Potassium Channels; Purkinje Cells; Reflex, Abnormal; Reflex, Vestibulo-Ocular | 2003 |
3,4-DAP-evoked transmitter release in hippocampal slices of aged rats with impaired memory.
Topics: 4-Aminopyridine; Acetylcholine; Aging; Amifampridine; Animals; Female; Hippocampus; Maze Learning; Memory Disorders; Neurotransmitter Agents; Norepinephrine; Organ Culture Techniques; Potassium Channel Blockers; Rats; Serotonin | 2003 |
[Formulation and stability of hospital preparation of 3,4-diaminopyridine capsules].
Topics: 4-Aminopyridine; Amifampridine; Capsules; Chemistry, Pharmaceutical; Drug Stability; Excipients | 2003 |
Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Acetylcholine; Action Potentials; Adolescent; Amifampridine; Biopsy; Carrier Proteins; Child; Cholinesterases; DNA Mutational Analysis; Electric Conductivity; Electromyography; Female; Gene Deletion; Humans; Immunohistochemistry; Male; Membrane Transport Proteins; Microscopy, Electron; Motor Endplate; Muscle Proteins; Muscle, Skeletal; Mutation; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Patch-Clamp Techniques; Potassium Channel Blockers; Receptors, Cholinergic; Vesicular Acetylcholine Transport Proteins; Vesicular Transport Proteins | 2004 |
Determination of A 3,4-diaminopyridine in plasma by liquid chromatography with electrochemical detection using solid-phase extraction.
Topics: 4-Aminopyridine; Amifampridine; Animals; Chromatography, High Pressure Liquid; Dogs; Electrochemistry; Female; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Combination of variable frequency train stimulation and K+ channel blockade to augment skeletal muscle force.
Topics: 4-Aminopyridine; Amifampridine; Animals; Diaphragm; Electric Stimulation; Isometric Contraction; Male; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley | 2004 |
Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 4-Aminopyridine; Adipose Tissue; Amifampridine; Animals; Apamin; Barium; Cromakalim; Delayed Rectifier Potassium Channels; Endothelin-1; Glyburide; Male; Mesenteric Artery, Superior; Peptides; Phenylephrine; Potassium; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Quaternary Ammonium Compounds; Rats; Rats, Sprague-Dawley; Serotonin; Tetraethylammonium; Vascular Resistance; Vasodilation; Viscera | 2004 |
Upbeat about downbeat nystagmus.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channels; Calcium Channels, N-Type; Calcium Channels, P-Type; Calcium Channels, Q-Type; Cerebellar Cortex; Female; Gravitation; Haplorhini; Humans; Male; Mice; Mice, Knockout; Models, Neurological; Nystagmus, Pathologic; Otolithic Membrane; Potassium Channel Blockers; Reflex, Abnormal; Reflex, Vestibulo-Ocular | 2004 |
Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus.
Topics: 4-Aminopyridine; Amifampridine; Cerebellum; Diplopia; Electronystagmography; Female; Gravitation; Head Movements; Humans; Middle Aged; Models, Neurological; Nystagmus, Pathologic; Otolithic Membrane; Postural Balance; Potassium Channel Blockers; Pursuit, Smooth; Reflex, Abnormal; Reflex, Vestibulo-Ocular; Video Recording; Vision Disorders | 2004 |
Cognitive deficits in aged rats correlate with levels of L-arginine, not with nNOS expression or 3,4-DAP-evoked transmitter release in the frontoparietal cortex.
Topics: 4-Aminopyridine; Acetylcholine; Aging; Amifampridine; Animals; Arginine; Cerebral Cortex; Cognition Disorders; Female; Frontal Lobe; Gene Expression Regulation; Nerve Tissue Proteins; Neurotransmitter Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Norepinephrine; Parietal Lobe; Rats; Rats, Long-Evans; Serotonin | 2005 |
Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
Topics: 4-Aminopyridine; Aged, 80 and over; Amifampridine; Cerebellum; Eye Movements; Female; Fixation, Ocular; Humans; Middle Aged; Nystagmus, Pathologic; Posture; Potassium Channel Blockers; Reflex, Vestibulo-Ocular | 2005 |
NCAM 180 acting via a conserved C-terminal domain and MLCK is essential for effective transmission with repetitive stimulation.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Animals, Newborn; Blotting, Western; Bungarotoxins; Computational Biology; Cysteamine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Electric Stimulation; Heterocyclic Compounds, 4 or More Rings; Humans; Immunohistochemistry; In Vitro Techniques; Mice; Mice, Knockout; Models, Neurological; Myosins; Neural Cell Adhesion Molecules; Neuromuscular Junction; Oligopeptides; PC12 Cells; Peptide Fragments; Peptides; Potassium Channel Blockers; Protein Structure, Tertiary; Rats; Signal Transduction; Synaptic Transmission; Xenopus | 2005 |
Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome.
Topics: 4-Aminopyridine; Adult; Amifampridine; Apgar Score; Drug Therapy, Combination; Female; Fetal Development; Humans; Infant, Newborn; Male; Myasthenic Syndromes, Congenital; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pyridostigmine Bromide | 2006 |
[Fatigue and episodic exhaustion as a feature of multiple sclerosis].
Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sedatives; Modafinil; Multiple Sclerosis; Severity of Illness Index; Surveys and Questionnaires | 2006 |
The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channels; Excitatory Postsynaptic Potentials; Kinetin; Neuromuscular Junction; Patch-Clamp Techniques; Potassium Channel Blockers; Presynaptic Terminals; Protein Kinase Inhibitors; Purines; Rana pipiens; Roscovitine; Synaptic Transmission; Xenopus laevis | 2006 |
Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products.
Topics: 4-Aminopyridine; Amifampridine; Chromatography, High Pressure Liquid; Drug Stability; Hydrogen Peroxide; Indicators and Reagents; Kinetics; Reference Standards; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet | 2007 |
Inotropic effects of the K+ channel blocker 3,4-diaminopyridine: differential responses of rat soleus and extensor digitorum longus.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Electric Stimulation; In Vitro Techniques; Isometric Contraction; Male; Muscle, Skeletal; Rats; Rats, Sprague-Dawley | 2006 |
Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.
Topics: 4-Aminopyridine; Adolescent; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Potassium Channel Blockers; Pyridostigmine Bromide; Thymectomy | 2007 |
Potassium initiates vasodilatation induced by a single skeletal muscle contraction in hamster cremaster muscle.
Topics: 4-Aminopyridine; Amifampridine; Animals; Arterioles; Barium Compounds; Chlorides; Cricetinae; Electric Stimulation; Enzyme Inhibitors; Male; Mesocricetus; Muscle Contraction; Muscle, Skeletal; Ouabain; Potassium; Potassium Channel Blockers; Potassium Channels; Sodium-Potassium-Exchanging ATPase; Time Factors; Vasodilation | 2007 |
Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
Topics: 4-Aminopyridine; Adult; Amifampridine; Cerebellar Diseases; Humans; Magnetic Resonance Imaging; Male; Nystagmus, Pathologic; Potassium Channel Blockers | 2007 |
Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins; Botulinum Toxins, Type A; Drug Resistance; Excitatory Postsynaptic Potentials; Male; Mice; Motor Neurons; Muscle Contraction; Muscle Weakness; Muscle, Skeletal; Muscular Atrophy; Neuromuscular Blockade; Neuromuscular Blocking Agents; Neuromuscular Junction; Neuronal Plasticity; Organ Size; Paralysis; Potassium Channel Blockers; Presynaptic Terminals; Recovery of Function | 2007 |
[Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Pyridostigmine Bromide; Treatment Outcome | 2007 |
Inotropic effects of the K+ channel blocker 3,4-diaminopyridine on fatigued diaphragm muscle.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Diaphragm; Electric Stimulation; Electrophysiology; Isometric Contraction; Male; Membrane Potentials; Muscle Contraction; Muscle Fatigue; Muscle Relaxation; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley; Respiratory Muscles; Stimulation, Chemical | 2008 |
[Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma].
Topics: 4-Aminopyridine; Amifampridine; Carcinoma, Squamous Cell; Cholinesterase Inhibitors; Electrophysiology; Endoscopy; Exercise; Humans; Lambert-Eaton Myasthenic Syndrome; Laryngeal Neoplasms; Male; Middle Aged; Muscular Diseases; Neural Conduction; Potassium Channel Blockers; Pyridostigmine Bromide; Ulnar Nerve; Vocal Cords; Voice Disorders | 2008 |
Mechanisms of neuromodulation as dissected using Sr2+ at motor nerve endings.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium; Carbazoles; Cyclic AMP; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Evoked Potentials; In Vitro Techniques; Nerve Endings; Neuromuscular Junction; Neurotransmitter Agents; Potassium Channel Blockers; Pyrroles; Ranidae; Statistics, Nonparametric; Strontium; Thionucleotides | 2008 |
Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation.
Topics: 4-Aminopyridine; Amifampridine; Animals; Cardiotonic Agents; Electric Stimulation; Evoked Potentials, Motor; Isometric Contraction; Muscle Fatigue; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley | 2008 |
[Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency].
Topics: 4-Aminopyridine; Adolescent; Amifampridine; Diagnosis, Differential; Humans; Male; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Pyridinium Compounds; Receptors, Cholinergic; Treatment Outcome | 2009 |
[A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Aged; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Potassium Channel Blockers; Small Cell Lung Carcinoma | 2009 |
Improvement of diaphragm and limb muscle isotonic contractile performance by K+ channel blockade.
Topics: 4-Aminopyridine; Amifampridine; Animals; Diaphragm; Extremities; Isotonic Contraction; Muscle Fatigue; Muscle, Skeletal; Organ Culture Techniques; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley | 2010 |
The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
Topics: 4-Aminopyridine; Amifampridine; Ataxia; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Humans; Male; Nystagmus, Congenital; Posture; Potassium Channel Blockers; Spinocerebellar Ataxias; Treatment Outcome | 2010 |
Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.
Topics: 4-Aminopyridine; Acetylcholine; Amifampridine; Animals; Antidotes; Botulinum Toxins, Type A; Calcium; Cell Line, Tumor; Cinnamates; Hydroxamic Acids; In Vitro Techniques; Metalloexopeptidases; Mice; Muscle Contraction; Muscle, Skeletal; Neuromuscular Junction; Reflex | 2010 |
Anharmonic vibrational analysis of 3,4-diaminopyridine and 3-aminopyridine by density functional theory calculations.
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Models, Molecular; Models, Theoretical; Molecular Structure; Potassium Channel Blockers; Quantum Theory; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Thermodynamics; Vibration | 2010 |
The price you pay.
Topics: 4-Aminopyridine; Amifampridine; Drug Approval; Drug Costs; European Union; Humans; Lambert-Eaton Myasthenic Syndrome; Orphan Drug Production; Potassium Channel Blockers | 2010 |
A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel function.
Topics: 4-Aminopyridine; Amifampridine; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cholinesterase Inhibitors; Disease Models, Animal; Gene Expression Regulation; Humans; Muscles; Mutation; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Potassium Channel Blockers; Protein Structure, Secondary; Pyridostigmine Bromide; Receptors, Nicotinic; Swimming | 2011 |
Open letter to prime minister David Cameron and health secretary Andrew Lansley.
Topics: 4-Aminopyridine; Amifampridine; Drug Costs; Drug Industry; European Union; Humans; Licensure; Orphan Drug Production; Rare Diseases; United Kingdom | 2010 |
Orphan drugs. BioMarin Europe replies.
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Orphan Drug Production; Potassium Channel Blockers | 2010 |
Orphan drugs. Regulation is flawed.
Topics: 4-Aminopyridine; Amifampridine; Drug Approval; Humans; Orphan Drug Production; Potassium Channel Blockers; Quality Control; Randomized Controlled Trials as Topic | 2010 |
Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Chromatography, High Pressure Liquid; Drug Compounding; Drug Contamination; Drug Labeling; Humans; Lambert-Eaton Myasthenic Syndrome; Potassium Channel Blockers; Quality Control | 2012 |
Role of calcium-activated potassium channels in the genesis of 3,4-diaminopyridine-induced periodic contractions in isolated canine coronary artery smooth muscles.
Topics: 4-Aminopyridine; Adrenergic beta-Agonists; Amifampridine; Animals; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Chloride; Coronary Vessels; Dogs; Hydrogen-Ion Concentration; In Vitro Techniques; Ion Channels; Male; Membrane Potentials; Mitochondria, Muscle; Muscle Contraction; Muscle, Smooth, Vascular; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Sarcoplasmic Reticulum; Sodium-Calcium Exchanger; Sodium-Potassium-Exchanging ATPase | 2011 |
Single-pixel optical fluctuation analysis of calcium channel function in active zones of motor nerve terminals.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Bungarotoxins; Calcium; Calcium Channels; Computer Simulation; Electric Stimulation; Freeze Fracturing; In Vitro Techniques; Models, Neurological; Monte Carlo Method; Muscle, Skeletal; Neuromuscular Junction; Optics and Photonics; Potassium Channel Blockers; Presynaptic Terminals; Rana pipiens; Receptors, Nicotinic; Synaptic Vesicles | 2011 |
Clinical features in a series of fast channel congenital myasthenia syndrome.
Topics: 4-Aminopyridine; Adult; Amifampridine; Child; Child, Preschool; Humans; Infant; Middle Aged; Muscle Weakness; Mutation; Myasthenic Syndromes, Congenital | 2012 |
[Aminopyridines for symptomatic treatment of multiple sclerosis].
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Evidence-Based Medicine; Humans; Lower Extremity; Multiple Sclerosis; Muscle Strength; Potassium Channel Blockers; Walking | 2011 |
3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Disease Models, Animal; Female; Mice; Myasthenia Gravis, Autoimmune, Experimental; Neuromuscular Junction; Potassium Channel Blockers; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2012 |
Recurrent COLQ mutation in congenital myasthenic syndrome.
Topics: 4-Aminopyridine; Acetylcholinesterase; Adolescent; Amifampridine; Child; Collagen; DNA Mutational Analysis; Female; Humans; Infant; Male; Muscle Proteins; Mutation; Myasthenic Syndromes, Congenital; Potassium Channel Blockers | 2012 |
Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.
Topics: 4-Aminopyridine; Adult; Amifampridine; Cholinesterase Inhibitors; Female; Glycosylation; Humans; Lower Extremity; Male; Middle Aged; Motor Endplate; Mutation; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Receptors, Cholinergic; Transferases (Other Substituted Phosphate Groups); Tunicamycin | 2012 |
Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins, Type A; Diaphragm; Male; Mice; Paralysis; Phrenic Nerve; Purines; Roscovitine | 2012 |
Ectopic uterine tissue as a chronic pain generator.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Antineoplastic Agents, Hormonal; Biophysics; Calcitonin Gene-Related Peptide; Cells, Cultured; Chronic Pain; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Endometriosis; Endometrium; Estrous Cycle; Female; Ganglia, Spinal; GAP-43 Protein; Hyperalgesia; Lectins; Leuprolide; Muscle, Skeletal; Nerve Fibers; Patch-Clamp Techniques; Potassium Channel Blockers; Progesterone; Progestins; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Tetraethylammonium; Time Factors; Transplants; Uterus | 2012 |
Blueberry juice causes potent relaxation of rat aortic rings via the activation of potassium channels and the H₂S pathway.
Topics: 4-Aminopyridine; Alkynes; Amifampridine; Animals; Antioxidants; Aorta; Beverages; Blueberry Plants; Glycine; Hydrogen Sulfide; In Vitro Techniques; Norepinephrine; Polyphenols; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Rats; Rats, Sprague-Dawley; Vasodilator Agents | 2013 |
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Cholinesterase Inhibitors; Evoked Potentials; Female; Humans; Immunoglobulin G; Mice; Mice, Inbred C57BL; Muscle Weakness; Muscle, Skeletal; Myasthenia Gravis, Autoimmune, Experimental; Neuromuscular Junction; Pyridostigmine Bromide; Receptor Protein-Tyrosine Kinases; Receptors, Cholinergic | 2013 |
Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.
Topics: 4-Aminopyridine; Adrenergic beta-2 Receptor Agonists; Adult; Age of Onset; Albuterol; Amifampridine; Biopsy; Cholinesterase Inhibitors; Diagnosis, Differential; DNA Mutational Analysis; Exome; Female; Genetic Testing; Glycosylation; Humans; Male; Middle Aged; Motor Neurons; Muscle, Skeletal; Myasthenic Syndromes, Congenital; N-Acetylglucosaminyltransferases; Neurologic Examination; Neuromuscular Junction; Phenotype; Potassium Channel Blockers; Pyridostigmine Bromide | 2013 |
Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia.
Topics: 4-Aminopyridine; Aged; Amifampridine; Base Sequence; DNA Mutational Analysis; Electromyography; Exome; Female; Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing); High-Throughput Nucleotide Sequencing; Humans; Molecular Sequence Data; Myasthenia Gravis; Myasthenic Syndromes, Congenital; Neostigmine; Neuromuscular Junction; Pedigree; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Acute and chronic effects of botulinum neurotoxin a on the mammalian neuromuscular junction.
Topics: 4-Aminopyridine; Acetylcholine; Acetylcholinesterase; Amifampridine; Animals; Botulinum Toxins, Type A; Calcium Ionophores; Cell Line, Tumor; Electric Stimulation; Electromyography; Evoked Potentials, Motor; In Vitro Techniques; Ionomycin; Mice; Mice, Inbred C57BL; Neuroblastoma; Neuromuscular Agents; Neuromuscular Junction; Potassium Channel Blockers; Reflex; Time Factors | 2014 |
Synthesis, characterization, and thermodynamics of some new unsymmetrical Schiff bases of salicylaldehyde with 3,4-diaminopyridine and their cobalt(III) complexes.
Topics: 4-Aminopyridine; Aldehydes; Amifampridine; Cobalt; Coordination Complexes; Magnetic Resonance Spectroscopy; Schiff Bases; Spectrophotometry, Infrared; Thermodynamics | 2014 |
Lack of neuropathy-related phenotypes in hint1 knockout mice.
Topics: 4-Aminopyridine; Amifampridine; Animals; Anxiety; Axons; Behavior, Animal; Electromyography; Immunohistochemistry; Isaacs Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Muscle, Skeletal; Mutation; Nerve Tissue Proteins; Peripheral Nervous System Diseases; Phenotype; Postural Balance; Potassium Channel Blockers; Psychomotor Performance | 2014 |
A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Antitoxin; Botulinum Toxins; Drug Therapy, Combination; Female; Kinetics; Mice; Neurotoxicity Syndromes; Potassium Channel Blockers; Sequestering Agents; Survival Analysis | 2014 |
Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channel Agonists; Cell Line, Tumor; Drug Synergism; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Mice; Neuromuscular Junction; Potassium Channel Blockers; Purines; Synaptic Potentials; Thiophenes | 2014 |
[Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy].
Topics: 4-Aminopyridine; Adult; Amifampridine; Diagnosis, Differential; Female; Humans; Menstrual Cycle; Muscle Proteins; Muscular Dystrophy, Facioscapulohumeral; Mutation; Myasthenic Syndromes, Congenital; Periodicity; Potassium Channel Blockers; Treatment Outcome | 2014 |
Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient.
Topics: 4-Aminopyridine; Aged; Amifampridine; Female; Humans; Muscle Proteins; Mutation; Myasthenic Syndromes, Congenital | 2015 |
Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Topics: 4-Aminopyridine; Adult; Amifampridine; Calcium Channels; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Potassium Channel Blockers | 2015 |
Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Child; Electrophysiological Phenomena; Female; Humans; Male; Middle Aged; Mutation; Myasthenic Syndromes, Congenital; Potassium Channel Blockers; Pyridostigmine Bromide; Reflex; Synaptic Transmission; Synaptotagmin II; Young Adult | 2015 |
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Amifampridine; Humans; Neuromuscular Junction Diseases; Orphan Drug Production; Physicians; Potassium Channel Blockers | 2016 |
Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Child, Preschool; Cholinesterase Inhibitors; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscle Proteins; Mutation; Myasthenic Syndromes, Congenital; Phenotype; Potassium Channel Blockers; Pyridostigmine Bromide; Young Adult | 2016 |
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Female; Humans; Middle Aged; Myasthenia Gravis; Receptor Protein-Tyrosine Kinases; Receptors, Cholinergic | 2016 |
Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication.
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Botulinum Toxins, Type A; Capsules; Lycopodium; Microscopy, Electron, Scanning | 2016 |
Resistance to protein adsorption and adhesion of fibroblasts on nanocrystalline diamond films: the role of topography and boron doping.
Topics: 4-Aminopyridine; Actins; Amifampridine; Blood Proteins; Boron; Cell Adhesion; Cell Proliferation; Cells, Cultured; Diamond; Fibroblasts; Humans; Materials Testing; Membranes, Artificial; Nanoparticles; Surface Properties | 2016 |
Effect of 3,4-diaminopyridine at the murine neuromuscular junction.
Topics: 4-Aminopyridine; Acetamides; Amifampridine; Animals; Calcium; Diaphragm; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Membrane Potentials; Mice; Mice, Inbred C57BL; Neuromuscular Junction; Potassium Channel Blockers; Synaptic Transmission | 2017 |
Amifampridine phosphate in congenital myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Child, Preschool; Electroencephalography; Female; Humans; Male; Mutation; Myasthenic Syndromes, Congenital; Potassium Channel Blockers; Receptors, Nicotinic | 2016 |
Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Neural Conduction; Palliative Care; Potassium Channel Blockers; Terminally Ill; Tomography, X-Ray Computed | 2016 |
L-type calcium channels refine the neural population code of sound level.
Topics: 4-Aminopyridine; Acoustic Stimulation; Action Potentials; Amifampridine; Animals; Biophysical Phenomena; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Excitatory Amino Acid Antagonists; In Vitro Techniques; Inferior Colliculi; Mice; Mice, Inbred CBA; Neurons; Nimodipine; omega-Conotoxin GVIA; Potassium Channel Blockers; Quinoxalines; Sound; Wakefulness | 2016 |
A response to a recent editorial by concerned physicians on 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Amifampridine; Humans; Orphan Drug Production | 2017 |
Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.
Topics: 4-Aminopyridine; Activities of Daily Living; Adult; Amifampridine; Azathioprine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome | 2017 |
The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome.
Topics: 4-Aminopyridine; Amifampridine; Direct-to-Consumer Advertising; Drug Compounding; Humans; Lambert-Eaton Myasthenic Syndrome; Marketing; Orphan Drug Production; Potassium Channel Blockers; Qualitative Research; Retrospective Studies | 2018 |
3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins, Type A; Diaphragm; Male; Mice; Mice, Inbred C57BL; Organ Culture Techniques; Potassium Channel Blockers; Respiratory Paralysis | 2018 |
[A retrospective study of the effects of 3,4-diaminopyridine treatment in Lambert-Eaton myasthenic syndrome].
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Potassium Channel Blockers; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2018 |
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cholinesterase Inhibitors; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Myasthenia Gravis; Potassium Channel Blockers; Pyridostigmine Bromide | 2018 |
3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome: Concerns regarding presentation of previous studies.
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Muscle Weakness; Potassium Channel Blockers | 2018 |